s3.pgkb.org1000trueattachment/0000-test.txt2019-03-01T00:03:02.000Z"c0b42597679cef994dc24566f76dba18"15STANDARDattachment/19300381.pdf2016-11-16T19:45:20.000Z"e889ba547ad8e06f6ecd7da1782787ca"48532STANDARDattachment/19300385.pdf2016-11-16T19:45:20.000Z"57d6b299a2513a352fff5bf86db2af87"51660STANDARDattachment/19300390.pdf2016-11-16T19:45:20.000Z"b1c6480e26f5105b82d5834f97bfb77e"90073STANDARDattachment/2019_Racc-analisi-farmacogenetiche_v26.3.2020.pdf2023-08-08T13:05:08.000Z"4a22113b15585139c2a603016c26d4b9"392862STANDARDattachment/24598717-supplement.pdf2017-06-02T18:54:13.000Z"dbf76bddfedd55618ac211fb8ed28a1c"667127STANDARDattachment/34216021.pdf2021-07-23T21:13:35.000Z"f509d28f8ed98aec7ebb890fe6b2dcca"812719STANDARDattachment/36443464_SuppTable1.pdf2022-12-08T02:00:28.000Z"4168161d3e3983cc22e5ca469d9f16e2"104124STANDARDattachment/5-hydroxypimozide.png2021-01-12T17:59:13.000Z"ad1b166fe0e035687dc58833e8c4ca14"51880STANDARDattachment/6-hydroxypimozide.png2021-01-12T17:58:58.000Z"9d5e7c4bc9e04e2c361200b43b5c6fad"56251STANDARDattachment/6-methoxy-8-hydroxylaminoquinoline.png2024-02-05T16:28:27.000Z"3b99a8cdafb95ccadf29242b018a2336"18408STANDARDattachment/7-COOH-CBD.png2020-11-12T13:55:51.000Z"726a1968dfb8347ad2b7fcc87b444c45"56671STANDARDattachment/ABCB1_VIP_Summary.pdf2024-10-19T06:14:51.000Z"6b2fa0c5aba7222cab37aa2334ecfee8"126613STANDARDattachment/ABCG2-Gene_Resource_Mappings.xlsx2022-02-15T20:56:30.000Z"c5f23a7960455eda45dd0f08bc554d91"9860STANDARDattachment/ABCG2.pdf2022-09-16T16:04:16.000Z"ae19911277174b1adaff2d3eab24cf34"56606STANDARDattachment/ABCG2_Diplotype_Phenotype_Table.xlsx2022-02-15T20:55:31.000Z"474e1ef7112cc9951eb16bde8b9678b8"4424STANDARDattachment/ABCG2_allele_definition_table.xlsx2023-05-04T04:53:51.000Z"b053fbc81e4dde87acdece5193a13051"5134STANDARDattachment/ABCG2_allele_functionality_table.xlsx2022-02-15T20:57:36.000Z"6bd35ad45fae48005822563393e4b65b"11149STANDARDattachment/ABCG2_frequency_table.xlsx2022-02-25T03:24:47.000Z"6f4319625ccc29e803c5ba21447e5801"11554STANDARDattachment/ABL1_VIP_Summary.pdf2024-10-19T06:15:02.000Z"edcfdff1d86e8c69f233243460283ba9"38298STANDARDattachment/ACMG_logo.png2016-11-16T19:46:53.000Z"5fc33b7feb9ec3a97ea268ea8a7a8d81"6273STANDARDattachment/ADH1A_VIP_Summary.pdf2024-10-19T06:15:10.000Z"80b7345997c37e8d5e5a6a160b092f5d"47723STANDARDattachment/ADH1B_VIP_Summary.pdf2024-10-19T06:15:16.000Z"614d6a6c40678f71978af7e5b0ac5aee"54979STANDARDattachment/ADH1C_VIP_Summary.pdf2024-10-19T06:15:22.000Z"b93763f670c28dbcd4ab01cb6696bf9d"40838STANDARDattachment/ADRB1_VIP_Summary.pdf2024-10-19T06:15:28.000Z"e79e9eb4c0ae49344e9e9c6932e3c56b"101294STANDARDattachment/AHR_VIP_Summary.pdf2024-10-19T06:15:34.000Z"0819732c0f4645a1300496b0e705b37b"46804STANDARDattachment/ALDH1A1_VIP_Summary.pdf2024-10-19T06:15:40.000Z"01d9fe9d9e8669fa43adb6586942785a"55725STANDARDattachment/ALK_VIP_Summary.pdf2024-10-19T06:15:47.000Z"15be8c37038cdb37413ad98d0278ebc5"41440STANDARDattachment/ALOX5_VIP_Summary.pdf2024-10-19T06:15:53.000Z"775edcd7535197aeae22c28361ba4d46"66015STANDARDattachment/Abacavir_03_01_16_FDA.pdf2016-11-16T19:47:11.000Z"69c7780759d8705382a7efaf823c3cc9"772908STANDARDattachment/Abacavir_03_02_16_HCSC.PDF2016-11-16T19:47:01.000Z"28c7ccf541c7fdbb1c15ae457efa61bf"612401STANDARDattachment/Abacavir_06_09_2018_FDA.pdf2018-11-15T18:44:39.000Z"1a85ce3ad537e8dbee72aad5d1db981f"1944526STANDARDattachment/Abacavir_06_18_19_EMA.pdf2019-06-18T23:05:22.000Z"903fc89eb5b5115dae87704413eaf863"1170071STANDARDattachment/Abacavir_11_15_2018_FDA.pdf2018-11-15T18:45:36.000Z"1a85ce3ad537e8dbee72aad5d1db981f"1944526STANDARDattachment/Abacavir_9_10_24_AEMPS.pdf2024-09-10T19:12:42.000Z"fdf4cbb4e7425e63a901e7861922e1ae"373386STANDARDattachment/Abacavir_EMA_EPAR_10_15_2012.pdf2016-11-16T19:45:38.000Z"987d55ce322a273aa4365b8304a2fc86"400900STANDARDattachment/Abacavir_FDA_Label_approved_Sept-11-2013.pdf2016-11-16T19:44:56.000Z"773f5931b45b89ae5f95e8fe96e6f67c"572933STANDARDattachment/Abacavir_HCSC_05_04_15.pdf2016-11-16T19:46:38.000Z"7d1fc666adc6d57781fdcc1742191abe"541368STANDARDattachment/Abacavir_PMDA_11_17_14.pdf2016-11-16T19:46:23.000Z"f1feb1767f27a9e4fa2d824e587024ed"880464STANDARDattachment/Abacavir_Pathway_Fig_1_7_16_2013.jpg2016-11-16T19:45:07.000Z"763fbaddf9ce59e347ea4b61d6024455"20759STANDARDattachment/Abemaciclib_06_18_19_EMA.pdf2019-06-18T23:10:31.000Z"93db4da40fdcd4b923ac56a0d4e3efa5"719600STANDARDattachment/Abemaciclib_11_15_2018_FDA.pdf2018-11-15T19:06:50.000Z"0a257f8c1c8cb06fec531454d60f3605"1802017STANDARDattachment/Abemaciclib_2022_06_30_EMA.pdf2022-07-08T17:22:52.000Z"90c09af775df84ca63f0d1b47b05dd97"1380336STANDARDattachment/Abemaciclib_2022_06_30_HSCS.pdf2022-07-02T00:47:45.000Z"4393d0294068f2b2866f02b0de4794d7"2437095STANDARDattachment/Abemaciclib_FDA_02_12_18.pdf2018-02-15T21:22:02.000Z"832fbb70f26ac33afb32d610e4d9fb4f"1101262STANDARDattachment/Abemaciclib_FDA_04042022.pdf2022-04-05T13:15:09.000Z"813ef7d010feb5b0bf68063eae3ce737"1773763STANDARDattachment/Abiraterone_02_27_2015_FDA.pdf2016-11-16T19:47:20.000Z"73197d8a5853cbcdaef6e0150bb77f0f"723196STANDARDattachment/Abiraterone_11_15_2018_FDA.pdf2018-11-28T18:55:07.000Z"802eba15b22f9725656e9885e5a2fbae"1211838STANDARDattachment/Abrocitinib_EMA_2022_07_08.pdf2022-07-08T14:15:42.000Z"f758b4937c6df7da0ccf0275db58aa08"592678STANDARDattachment/Abrocitinib_FDA_2022_07_08.pdf2022-07-08T14:10:41.000Z"f30a81a17babb8332145fbc31a021c61"548487STANDARDattachment/Abrocitinib_HCSC_2022_07_08.pdf2022-07-08T15:50:52.000Z"abafc71740e910a34f8e61cf6280ab51"1159887STANDARDattachment/Acalabrutinib_EMA_2026_03_18.pdf2026-03-19T12:54:27.000Z"1696c7ea20cfca4b498ab0a04d9bb85f"CRC64NVMEFULL_OBJECT2075764STANDARDattachment/Acalabrutinib_FDA_2026_03_18.pdf2026-03-18T18:58:18.000Z"1334a221df9f98de8d331c8250932c7d"CRC64NVMEFULL_OBJECT1373766STANDARDattachment/Acalabrutinib_HCSC_2026_03_18.pdf2026-03-19T12:56:25.000Z"4270bc732d655138c03991bd9299be27"CRC64NVMEFULL_OBJECT1203554STANDARDattachment/Acenocoumarol_9_10_24_AEMPS.pdf2024-09-10T21:53:57.000Z"54d7476863666266d7975c42b86ea543"279432STANDARDattachment/Acetaminophen_12_1_2022.pdf2022-12-01T17:59:39.000Z"3ad9dd9d82fe96c4d725830d664d30c5"630703STANDARDattachment/Acetaminophen_Caffeine_Dihydrocodeine_07_12_21_FDA.pdf2021-07-12T17:37:19.000Z"44c9e1bc3bae4733dcb4435c147b2ac0"403907STANDARDattachment/Acetaminophen_and_Tramadol_HCSC_03_24_15.pdf2016-11-16T19:47:26.000Z"5283ca6b55f5933404875c5c93d60f17"948476STANDARDattachment/Acetaminophen_and_Tramadol_HCSC_05_04_15.pdf2016-11-16T19:46:54.000Z"7ceb41e8bc85aa0573852f6b79b53f9a"932472STANDARDattachment/Acetaminophen_and_tramadol_FDA_drug_label_Oct-15-2013.pdf2016-11-16T19:44:24.000Z"ac3d14fcc2bc181a50ba0a3d0b13e3e4"313432STANDARDattachment/Acoramidis_FDA_2026_03_16.pdf2026-03-16T13:17:41.000Z"aa4048af90df91feebc4a9baccb13f55"CRC64NVMEFULL_OBJECT855646STANDARDattachment/Acyclovir_FDA_09082021.pdf2021-09-08T17:19:26.000Z"6d85e03189de065414f92fdb19df8334"456616STANDARDattachment/Adagrasib_2024_12_05_EMA.pdf2024-12-05T17:28:23.000Z"253750896ea966d7702b14b4fd1fd96f"224075STANDARDattachment/Adagrasib_FDA_2023_03_15.pdf2023-03-15T14:17:47.000Z"797eccbbcfc895f2502c5951be5fa8db"542580STANDARDattachment/Adcetris_EMA_EPAR_12_17_2012.pdf2016-11-16T19:45:17.000Z"79247b902bcbd382e5fd5f4e75604714"203338STANDARDattachment/Aducanumab-avwa_2024_09_09_FDA.pdf2024-09-09T23:16:13.000Z"6595b154792e8189da2b7e8b158b27a9"791198STANDARDattachment/Aerinaze_EMA_EPAR_12_17_2012.pdf2016-11-16T19:45:04.000Z"c1c14abd3f301bf7b58a3660d22e1c1c"170444STANDARDattachment/Afatinib_06_18_19_EMA.pdf2019-06-18T23:26:02.000Z"8836ab250826a3c7ebea8ab2d155989c"1252430STANDARDattachment/Afatinib_06_21_2017_FDA.pdf2018-11-28T19:03:14.000Z"e0ef529c79f7aba0f2ed749dd669d8ef"466402STANDARDattachment/Afatinib_12_16_2013_FDA.pdf2016-11-16T19:45:50.000Z"b91e4f522fd5c850cf8d6d905a23fbd7"361820STANDARDattachment/Afatinib_EMA_EPAR_May_1_2014.pdf2016-11-16T19:46:00.000Z"75980946a7bb94ac192e553730207147"699354STANDARDattachment/Afatinib_HCSC_05_05_15.pdf2016-11-16T19:46:54.000Z"6b0e9ffd9b1b504f457b4701cbeb6852"652555STANDARDattachment/Aficamten_EMA_2026_03_18.pdf2026-03-18T14:21:36.000Z"f63b8307cc9da5ad4beba4c54a41220d"CRC64NVMEFULL_OBJECT464867STANDARDattachment/Aficamten_FDA_2026_03_10.pdf2026-03-10T13:03:07.000Z"2dd82d318e3275f5a19c21550700d977"CRC64NVMEFULL_OBJECT3197894STANDARDattachment/Afinitor_EMA_EPAR_Jan_09_2012.pdf2016-11-16T19:45:04.000Z"b0213f0cd85892689628faa73cb08869"716979STANDARDattachment/Afutuzumab_12_07_17_FDA.pdf2018-11-28T19:11:01.000Z"2a440a0c95a27bccef188d08d149f976"980220STANDARDattachment/Afutuzumab_7_14_14_FDA.pdf2016-11-16T19:46:17.000Z"c0d43a0d91c0265ea4d9eeb71b02afa0"505819STANDARDattachment/Afutuzumab_HCSC_12.21.15.PDF2016-11-16T19:47:40.000Z"e13996d6d16c238a71293551c0d8869e"831797STANDARDattachment/Albendazole_3_30_2022.pdf2022-03-30T18:08:18.000Z"67bb0eccd6facb05681f680e648e2b2f"345180STANDARDattachment/Alectinib_06_18_19_EMA.pdf2019-06-18T23:35:10.000Z"77e2ebd2e5e4cd0089829d99699f4285"678601STANDARDattachment/Alectinib_2024_08_19_FDA.pdf2024-08-19T17:44:38.000Z"ddbb9eac9789f0a4048f91ec8ba9382a"585736STANDARDattachment/Alectinib_FDA_06_21_2017.pdf2018-11-28T19:39:11.000Z"4521689aed89d4bb04a53d2d2a2ff5af"428880STANDARDattachment/Alectinib_FDA_08_17_16.pdf2016-11-16T19:47:42.000Z"5715708892fe5898a3a7a136d2f700cd"428042STANDARDattachment/Alectinib_HCSC_2023_01_11.pdf2023-01-11T16:46:51.000Z"00f74e7088036e75430b2644c6d6adbd"1443200STANDARDattachment/Alfentanil_FDA_2022_05_12.pdf2022-05-12T13:03:11.000Z"b2ad76f0d42d1e1d015f6b40c5ddd5cb"403635STANDARDattachment/Alglucosidase_Alfa_epar_01122020.pdf2020-12-01T21:48:24.000Z"08873f74a3640a6990cee659c4f28d1a"448863STANDARDattachment/Alirocumab_FDA_06_21_2017.pdf2018-11-28T19:41:23.000Z"44916f0d780eee1044c07eae2e48fb2f"1606812STANDARDattachment/Alirocumab_FDA_08_09_16.pdf2016-11-16T19:47:12.000Z"6a84aafa6a433213e51ab4c311f33be9"1623641STANDARDattachment/Aliskiren_HCSC_05.31.2016.PDF2016-11-16T19:47:40.000Z"41456e36c47385b25444397e067ff262"802479STANDARDattachment/Allele_ref_var_def.jpg2025-04-14T01:48:36.000Z"d9aaf779ad6b06e3877587659a60a800"CRC64NVMEFULL_OBJECT125746STANDARDattachment/Allopurinol_2025_08_29_HCSC.pdf2025-08-29T23:58:46.000Z"ebbec960512457ece78d82f0a9af3020"CRC64NVMEFULL_OBJECT389755STANDARDattachment/Allopurinol_2025_10_20_FDA.pdf2025-10-20T18:20:57.000Z"d98b18c6059addd97ffe4c46b58a0145"CRC64NVMEFULL_OBJECT322820STANDARDattachment/Allopurinol_9_11_24_AEMPS.pdf2024-09-11T21:29:06.000Z"2c909f5f4d38e19509b49f230fca1bb3"248221STANDARDattachment/Allopurinol_HSCS_2023_01_11.pdf2023-01-11T15:54:00.000Z"8daa06df027b7cc35758d1d73195765f"335434STANDARDattachment/Allopurinol_PMDA_10_03_16.pdf2016-11-16T19:47:44.000Z"1ae3d2fcb7a3b368d5cd123cc3f5ebe9"455142STANDARDattachment/Almotriptan_M6_metabolite.png2024-07-05T09:58:31.000Z"f7ef476b73049bbdac2767f5a1032b0d"39798STANDARDattachment/Almotriptan_M7_metabolite.png2024-07-05T09:58:40.000Z"2b39061b738ed5d90ed16cfc9ecb7aa6"44329STANDARDattachment/Almotriptan_M8_metabolite.png2024-07-05T09:58:47.000Z"8145b2bbdbc17be5b6c5c6bef01dae32"59552STANDARDattachment/Alpelisib_10_3_2019_FDA.pdf2019-10-03T17:51:41.000Z"0d1cb362b1a653d9486b72fcb6451c7c"440790STANDARDattachment/Alpelisib_12_07_20_EMA.pdf2020-12-07T17:39:27.000Z"3d92ff695043071e55fbe9242e59102f"821257STANDARDattachment/Altman_Klein_Whirl-Carrillo_and_JIPIC_Comments_re_LDT_Regulation_-_FINAL.pdf2016-11-16T19:47:06.000Z"4ab22563c50f4b4c9cf07c7b0055fce8"192255STANDARDattachment/Amifampridine_03_14_19_FDA.pdf2019-03-14T20:44:01.000Z"4b979ca5da1b03993fe3825455682bdc"949450STANDARDattachment/Amifampridine_06_18_19_EMA.pdf2019-06-18T23:44:37.000Z"86fda53704b6aa6fc5c2ed194e4983d0"453200STANDARDattachment/Amifampridine_phosphate_12_07_20_EMA.pdf2020-12-08T18:28:05.000Z"cbe97f8d11f1b548d82f03ea284ba68e"405256STANDARDattachment/Amifampridine_phosphate_12_07_20_HCSC.pdf2020-12-07T19:57:49.000Z"37096269b3cdf884011c8d1981443e79"322268STANDARDattachment/Amikacin_08_31_21_FDA.pdf2021-08-31T21:45:47.000Z"e0f40c65d5506c0977b19e0e0ecf9636"653817STANDARDattachment/Amikacin_2024_11_22_HCSC.pdf2024-11-22T21:31:35.000Z"fd95ac4f05022a061c59063769e82f6f"281441STANDARDattachment/Amikacin_9_11_24_AEMPS.pdf2024-09-11T22:05:02.000Z"228c762b3ebdd0febdee8ae7b9f0153e"336718STANDARDattachment/Amiodarone_FDA_2022_05_05.pdf2022-05-06T21:00:08.000Z"4b8fc37b9a876198d541fa46003a4cd6"623411STANDARDattachment/Amisulpride_12_2_2022.pdf2022-12-02T20:01:08.000Z"5701a085accf6b85a777a0d9a4d3e05f"1256568STANDARDattachment/Amitriptyline_11_28_2018_FDA.pdf2018-11-28T19:36:43.000Z"d148c09166dae1799e01addc757ce4cc"631734STANDARDattachment/Amitriptyline_2024_07_18_FDA.pdf2024-07-18T18:47:02.000Z"3231592ed1ae30245de180ca28887572"188401STANDARDattachment/Amitriptyline_2024_11_22_HCSC.pdf2024-11-22T22:05:23.000Z"555031e2a16e90d835c127ce16d05469"547415STANDARDattachment/Amitriptyline_9_11_24_AEMPS.pdf2024-09-18T18:13:20.000Z"ad405dab67aa631f1dcdf266e0260abe"308123STANDARDattachment/Amitriptyline_CYP2D6.pdf2016-11-16T19:45:12.000Z"7bc527ac3e5692cf758bf3e969881cdf"124507STANDARDattachment/Amivantamab-vmjw_2024_09_09_FDA.pdf2024-09-09T21:27:50.000Z"31dc9fd2daba67cb2613acabf3b9f519"1426900STANDARDattachment/Amivantamab_2024_09_09_EMA.pdf2024-09-09T21:49:36.000Z"a725246e3afdf24e3876b875fb69c3b6"502088STANDARDattachment/Amivantamab_2024_09_09_HCSC.pdf2024-09-09T21:40:52.000Z"18f27c7789f77fc4b24324d4625e762a"842841STANDARDattachment/Ammonaps_EMA_EPAR_Oct_27_2013.pdf2016-11-16T19:44:18.000Z"88d86c3a88e3baa59a7d91d6988a4718"220190STANDARDattachment/Amphetamine_2024_05_30_HCSC.pdf2024-05-30T18:37:41.000Z"1ea59bb909402cf9ce856d2399a8e26c"761811STANDARDattachment/Amphetamine_2024_07_26_FDA.pdf2024-07-26T23:39:31.000Z"5787eeeb0db0f81b7d74af3132cb2b99"1163373STANDARDattachment/Amphetamine_2025_07_16_FDA.pdf2025-07-16T20:39:31.000Z"8f7a76422ce019393c4be05e1937e1ef"CRC64NVMEFULL_OBJECT638480STANDARDattachment/Amphotericin_B_3_30_2022.pdf2022-03-30T18:16:39.000Z"e6687ada203f65841d5193f57bb3154d"209674STANDARDattachment/Ampicillin_FDA_05_05_2022.pdf2022-05-07T03:41:16.000Z"40e9f6fc466d94376dbb92466bb69484"1111235STANDARDattachment/Anakinra_2024_05_09_EMA.pdf2024-05-09T23:19:40.000Z"75e15e3fef0dc9cff5c373bb88ecc67c"437907STANDARDattachment/Anakinra_2024_05_09_HCSC.pdf2024-05-09T23:08:06.000Z"f4fef770d98316e2742588e3411b6e09"873994STANDARDattachment/Anastrozole_06_23_2017_FDA.pdf2018-11-28T19:48:18.000Z"edb3402b6188739eac88a681b6e70ea7"581438STANDARDattachment/Anastrozole_12_16_2013_FDA.pdf2016-11-16T19:45:49.000Z"844ec07d4dd668b430064972eeb70ada"478773STANDARDattachment/Anastrozole_2024_08_06_HCSC.pdf2024-08-06T13:16:54.000Z"b0695a64dca2bdbff72a3b416f2301f6"778149STANDARDattachment/Anastrozole_HCSC_05_05_15.pdf2016-11-16T19:46:39.000Z"7dff487d2a88c82e9effe71161daf555"886540STANDARDattachment/Anifrolumab_FDA_2022_08_30.pdf2022-08-30T14:48:14.000Z"bda7c2d9f76cf5f7edbd08bd50db4e1f"651039STANDARDattachment/Antiarrhythmic_Pathway_Pharmacodynamics_evidence.xls2017-06-09T20:05:01.000Z"2696005a1b8eada5449fdb111ac880fa"440832STANDARDattachment/Arformoterol_05_29_15_FDA.pdf2016-11-16T19:47:32.000Z"2ea68f44d9e6925e1e24e2014e5e58a1"525928STANDARDattachment/Arformoterol_06_23_2017_FDA.pdf2018-11-28T19:51:59.000Z"bb0e320c884ccf16ac470a9b203ba2e3"521882STANDARDattachment/Arimoclomol_2025_05_15_FDA.pdf2025-05-15T22:54:20.000Z"08806506f182ab6533c6a8ae3f041c74"CRC64NVMEFULL_OBJECT881477STANDARDattachment/Aripiprazol_9_17_24_AEMPS.pdf2024-09-18T18:22:13.000Z"037db94dd6c3eedd06b3d7e79cc0cb94"2674806STANDARDattachment/Aripiprazole_07_04_2017_FDA.pdf2018-11-28T22:06:56.000Z"c7b14fe0aedd6ee1f1c77aa15e50cf62"2719804STANDARDattachment/Aripiprazole_2024_09_20_HCSC.pdf2024-09-20T20:45:05.000Z"8b7db9ea8177f2a9d4f8b1672bbdf99a"677720STANDARDattachment/Aripiprazole_8_29_11.pdf2016-11-16T19:44:32.000Z"0cf42f160cdee29bc1a33a994839b122"300710STANDARDattachment/Aripiprazole_ABILIFY_06_18_19_EMA.pdf2019-06-19T00:11:15.000Z"47edaee75f08ec3480c2f71893cf13b5"1343409STANDARDattachment/Aripiprazole_ABILIFY_MAINTENA_06_18_19_EMA.pdf2019-06-19T00:11:22.000Z"96583b79f71654488ebbdd303e553145"1026708STANDARDattachment/Aripiprazole_AbilifyAsimtufii_2025_03_21_FDA.pdf2025-03-28T16:57:33.000Z"1081bc2281e948bde1f8d4a377dcc5e5"CRC64NVMEFULL_OBJECT1451815STANDARDattachment/Aripiprazole_AbilifyMaintenaAsimtufii_2025_03_28_HCSC.pdf2025-03-28T18:11:41.000Z"595e7452738759465012ef046274c8e9"CRC64NVMEFULL_OBJECT1725500STANDARDattachment/Aripiprazole_Abilify_01_17_19_FDA.pdf2019-03-04T19:23:26.000Z"fdac60ad12477c18610170562dd60b31"2837255STANDARDattachment/Aripiprazole_Abilify_Maintena_11_28_18_FDA.pdf2018-11-28T21:59:07.000Z"88ba02254421b4687607f1bb1750413d"2148223STANDARDattachment/Aripiprazole_FDA_drug_label_Oct_15_2013.pdf2016-11-16T19:44:25.000Z"67fc5c1d4c82ff642e0677120105c56e"9620248STANDARDattachment/Aripiprazole_HCSC_05_06_15.pdf2016-11-16T19:46:26.000Z"73c534389b9e7da4926154be2493c1b4"690026STANDARDattachment/Aripiprazole_Lauroxil_11_28_18_FDA.pdf2018-11-28T22:57:37.000Z"2083b1b952147a1d013cce76b8941163"1859295STANDARDattachment/Aripiprazole_Lauroxil_FDA_11_09_16.pdf2016-11-16T19:47:18.000Z"813b0d751d0ab64c0ed9403c87f7c765"1141920STANDARDattachment/Aripiprazole_Lauroxil_Initio_11_28_18_FDA.pdf2018-11-28T23:07:35.000Z"43d7481684ce9cdfe5ad9605666c4222"1278151STANDARDattachment/Arsenic_Trioxide_06_18_19_EMA.pdf2019-06-19T00:22:08.000Z"f0fdab66c83bb254c5c11bb5d30200a6"718032STANDARDattachment/Arsenic_Trioxide_11_29_18_FDA.pdf2018-11-29T20:20:48.000Z"c5f39fce2c99f44d5f767e1a11980cd1"1016408STANDARDattachment/Arsenic_Trioxide_PMDA_11_14_14.pdf2016-11-16T19:46:49.000Z"7c6d1822055eeec5533457d10ef4313c"439330STANDARDattachment/Arsenic_trioxide_2024_12_02_HCSC.pdf2024-12-02T18:47:13.000Z"5241e9acffebd9c949661f6061167771"839107STANDARDattachment/Arsenic_trioxide_6_27_2011.pdf2016-11-16T19:44:32.000Z"431e7d8e478b5e08ca45ebea3520a3cb"356259STANDARDattachment/Arsenic_trioxide_FDA_Label_Oct_17_2013.pdf2016-11-16T19:44:27.000Z"4629f583fe4ee8680b1b25b38536afc0"243654STANDARDattachment/Arsenic_trioxide_HCSC_05_06_15.pdf2016-11-16T19:47:21.000Z"423c0c3e758a8d6a5d62631788c571ac"576041STANDARDattachment/Artesunate_3_30_2022.pdf2022-03-30T15:33:23.000Z"7b865fa533e323b9d2b7d61edf60094c"368335STANDARDattachment/ArticaineAndEpinephrine_05_13_2019FDA.pdf2019-05-15T17:40:58.000Z"fa1a85f5e2ecddd57303024ef3b3b4fa"149719STANDARDattachment/Asciminib_2022_08_03_HCSC.pdf2022-08-04T00:08:13.000Z"e5829abd70498c7cb4677087cdb09a81"1156673STANDARDattachment/Asciminib_EMA_2023_10_11.pdf2023-10-11T14:01:21.000Z"a2e60ac4937d64dfd10c78cbe642efc4"587965STANDARDattachment/Asciminib_FDA_04052022.pdf2022-04-05T13:56:55.000Z"fc18f0ebcab272ddf683948b4dc3f027"874890STANDARDattachment/AscorbicAcid_FDA_2023_03_15.pdf2023-03-15T17:04:09.000Z"65157e9fc9d2fcfec5bc11893b0636d1"561701STANDARDattachment/Ascorbic_acid_2025_01_10_HCSC.pdf2025-01-10T22:09:58.000Z"eeb0a77d195d9a456ac6b42b29966891"329760STANDARDattachment/Atazanavir_02_06_18.pdf2018-02-06T16:02:50.000Z"30aa5ac6bc518d665c2911e018b27368"3380429STANDARDattachment/Atazanavir_06_17_19_EMA.pdf2019-06-19T17:09:57.000Z"25699a2279be393bb4c29b5222184cab"1563615STANDARDattachment/Atazanavir_2024_05_10_FDA.pdf2024-05-11T01:13:54.000Z"e0f6380ed76790ba289de24703d05c1c"883777STANDARDattachment/Atazanavir_2024_05_30_HSCS.pdf2024-05-30T21:15:47.000Z"575e7b5aa80866479410dcb0fe84b4ae"1470717STANDARDattachment/Atazanavir_2025_08_29_AEMPS.pdf2025-09-02T20:10:22.000Z"6439d2053a68ae31df39138f527464df"CRC64NVMEFULL_OBJECT575536STANDARDattachment/Atazanavir_PMDA_11_30_16.pdf2016-11-30T19:04:31.000Z"3bf9c99ea7cf3a3a0a8c582e86f64e02"753570STANDARDattachment/Atezolizumab_02_24_21_HCSC.pdf2021-03-01T19:00:47.000Z"f1452678484d1ab3a082d76ff0684618"2210116STANDARDattachment/Atezolizumab_03_21_17_FDA.pdf2017-03-21T20:11:35.000Z"6cf5dd04fa6a0e92374424108b04157a"854384STANDARDattachment/Atezolizumab_06_18_19_EMA.pdf2019-06-19T17:23:00.000Z"b4ade81b6dd817c882f473d28e1b0f65"1795443STANDARDattachment/Atezolizumab_11_29_18_FDA.pdf2019-10-04T17:00:26.000Z"263bf2a75a17d9a8fda6b283d8911677"564304STANDARDattachment/Atezolizumab_2025_01_09_EMA.pdf2025-01-09T18:19:42.000Z"78791f1d7d7128d1a3fc44dbd81b0bbd"2465351STANDARDattachment/Atezolizumab_FDA_04_04_2022.pdf2022-04-04T18:54:10.000Z"fbef10d34d46d94126b3aa92dd2b76bb"2686291STANDARDattachment/Atomoxetine_07_04_2017_FDA.pdf2018-11-29T20:57:54.000Z"3b017d5d47cb900827bc710ce92e06ee"1830495STANDARDattachment/Atomoxetine_10_1_24_AEMPS.pdf2024-10-01T19:04:50.000Z"20cf95e673d7230afcdea7c2c5f8919f"353908STANDARDattachment/Atomoxetine_2024_11_22_HCSC.pdf2024-12-02T18:27:36.000Z"e35255b396b7600adcf4260570092ce1"820485STANDARDattachment/Atomoxetine_8_30_11.pdf2016-11-16T19:44:32.000Z"1eca90a6c4f09a57ab385b127b577641"550523STANDARDattachment/Atomoxetine_FDA_label_Oct_17_2013.pdf2016-11-16T19:45:25.000Z"5e5d6d12a77bfe0d72abdb934a92a93b"580901STANDARDattachment/Atomoxetine_HCSC_05_07_15.pdf2016-11-16T19:47:31.000Z"24a4aa75d2e9f9d12e5b748715ace411"736040STANDARDattachment/Atomoxetine_PMDA_11_14_14.pdf2016-11-30T19:19:01.000Z"12f387863f9853dfd5eade23c62341ea"731459STANDARDattachment/Atorvastatin_07_04_2017_FDA.pdf2018-11-29T21:00:52.000Z"b200ba0bc09a62008330960dd83ce211"4538411STANDARDattachment/Atorvastatin_10_1_24_AEMPS.pdf2024-10-08T21:17:44.000Z"775bbc7552129e4bb439ecf1dd28955b"383951STANDARDattachment/Atorvastatin_FDA_2023_12_04.pdf2023-12-04T17:32:32.000Z"b8d5a89dc5f1795aab186b8b31eaedce"708917STANDARDattachment/Atorvastatin_FDA_label_Oct_17_2013.pdf2016-11-16T19:45:26.000Z"53308228f7e426390abcf1b594d9d8b5"738075STANDARDattachment/Atorvastatin_HCSC_05_07_15.pdf2016-11-16T19:46:26.000Z"33a450d87ae99fe7f6432d4867fe1092"810726STANDARDattachment/Atorvastatin_HCSC_05_16_16.pdf2016-11-16T19:46:44.000Z"2a0b38567b2032ab4b5feb3f3e49c0ea"883020STANDARDattachment/Atorvastatin_PMDA_10_03_16.pdf2016-11-16T19:47:44.000Z"045f337b5b3241b7f41591a7bfdf12ed"755575STANDARDattachment/Atorvastatin_PMDA_11_14_14.pdf2016-11-16T19:46:49.000Z"f50468b0f38c59c38f6ac4afd4402dfb"727496STANDARDattachment/Atorvastatin_Pre_and_Post_Test_Alerts.xlsx2022-02-16T03:04:15.000Z"93c795749488444fe4dc1851133e999e"16276STANDARDattachment/Atropine_3_30_2022.pdf2022-03-30T18:25:37.000Z"4c20e82d69512eb105866bea89b53f45"221595STANDARDattachment/Avapritinib_2024_10_15_HCSC.pdf2024-10-15T21:46:48.000Z"c81830bc6ecaf27220800500d05cd08a"581461STANDARDattachment/Avatrombopag_02_25_21_EMA.pdf2021-04-22T16:02:41.000Z"b5cfcc9b3323d7cd81f32c567e2f1891"448429STANDARDattachment/Avatrombopag_08_08_18_FDA.pdf2018-08-09T19:14:04.000Z"106f48e63df0f8ce05a6527be3132aed"800655STANDARDattachment/Avatrombopag_2024_07_11_EMA.pdf2024-07-12T22:15:15.000Z"bd91e9cf7f150f6438bdcf72f3543668"587332STANDARDattachment/Avatrombopag_2024_07_11_FDA.pdf2024-07-11T23:27:06.000Z"dba0be1b4845c74f5e8110fb7251aa06"793299STANDARDattachment/Avatrombopag_2024_07_11_HCSC.pdf2024-07-12T22:49:16.000Z"43099d197247f8ef4716bbb7302e969c"649647STANDARDattachment/Avelumab_08_25_17_FDA.pdf2017-08-29T20:21:33.000Z"5452aa6d4f4b3db87265506f7d2a9bba"414504STANDARDattachment/Avelumab_11_29_18_FDA.pdf2018-11-29T21:19:24.000Z"67efa68a05ffdd7ea0f68221440235f8"742884STANDARDattachment/Avelumab_2024_05_09_EMA.pdf2024-05-10T17:32:29.000Z"4de1b5b92fa2086e0f3c475f3195e380"602975STANDARDattachment/Avelumab_2024_05_09_HCSC.pdf2024-05-10T17:37:17.000Z"dc8f805db04f84a9a70dc1cb01392759"1247766STANDARDattachment/AvutometinibDefactinib_FDA_2026_03_13.pdf2026-03-13T17:30:40.000Z"dad1062b6ccd79ab38b880cec90d16c7"CRC64NVMEFULL_OBJECT759663STANDARDattachment/Axitinib_06_19_19_EMA.pdf2019-06-19T17:29:32.000Z"327c21ef9ecf16ee41171c302d84718f"480679STANDARDattachment/Axitinib_2024_05_30_FDA.pdf2024-05-30T22:13:18.000Z"558b62b9db7017d9a5de5e5af4b3517d"882528STANDARDattachment/Axitinib_2024_05_30_HCSC.pdf2024-05-31T23:03:00.000Z"c11b78125346aa9f073fa50a47c40991"1694083STANDARDattachment/Azacitidine_2024_08_05_HCSC.pdf2024-08-05T17:55:37.000Z"03b757b734d8d005937cad14d1e48b48"519013STANDARDattachment/Azacitidine_EMA_2022_09_06.pdf2022-09-07T14:12:44.000Z"e9da6d3648eed6eff3c454adcc6c590f"423151STANDARDattachment/Azacitidine_FDA_2022_09_06.pdf2022-09-06T18:46:39.000Z"ceb1d866006bae53c957b93c74f229e3"596692STANDARDattachment/Azacitidine_HCSC_2022_09_06.pdf2022-09-07T14:12:55.000Z"863658d7547132f704ede5318c7a729e"1375195STANDARDattachment/Azathioprine_05_10_19_FDA.pdf2019-05-10T21:23:05.000Z"81bb30c67d4e96ffd162ed97d84642f6"605607STANDARDattachment/Azathioprine_11_29_18_FDA.pdf2018-11-30T20:41:18.000Z"a40c7d6f6d19706b7ace2b29b7533db5"1248260STANDARDattachment/Azathioprine_2024_07_18_HCSC.pdf2024-07-18T22:12:58.000Z"8eab7a6d0d148c1116259398017830a4"584190STANDARDattachment/Azathioprine_9_17_24_AEMPS.pdf2024-10-01T19:14:47.000Z"cffe375928263de6d191f62e64992078"441635STANDARDattachment/Azathioprine_FDA_label_Oct_17_2013.pdf2016-11-16T19:45:27.000Z"ffb69f28076cfc92e53bdb84618135fe"256795STANDARDattachment/Azathioprine_HCSC_05_07_15.pdf2016-11-16T19:46:54.000Z"dc8506e35b4e16e4f82f4416fec98ef0"397120STANDARDattachment/Azathioprine_PMDA_10_03_16.pdf2016-11-16T19:47:44.000Z"90a404b7a3fc6b579eac5832adb56158"420886STANDARDattachment/Azathioprine_PMDA_11_14_14.pdf2016-11-16T19:47:06.000Z"a5bf8cc69538fad06e9a7a0470d726be"512904STANDARDattachment/Azithromycin_FDA_05_05_2022.pdf2022-05-12T21:10:28.000Z"6e1ffdea1ef6c0b5f9c6c95ca396234e"499179STANDARDattachment/BCR_VIP_Summary.pdf2024-10-19T06:15:59.000Z"d2c250d10e124e51665f61e50bb52e74"39132STANDARDattachment/BRAF_VIP_Summary.pdf2024-10-19T06:16:11.000Z"7fb24a70700249c7d6ca7847dede7289"41752STANDARDattachment/BRCA1_VIP_Summary.pdf2024-10-19T06:16:17.000Z"2bd1740b572cbdf812436903e147d75e"98944STANDARDattachment/BRENTUXIMAB_VEDOTIN_FDA_20230907.pdf2023-09-08T03:56:41.000Z"51c159e4398587a474fa6596d82ef344"1802648STANDARDattachment/Baclofen_Injection_3_30_2022.pdf2022-03-30T18:39:43.000Z"90debd6a18627894eb98a98b7d564707"181514STANDARDattachment/Baclofen_Oral_3_30_2022.pdf2022-03-30T18:50:12.000Z"94dd35d7dcc146721530c81aefccca96"474155STANDARDattachment/BelantamabMafodotin_FDA_2026_03_19.pdf2026-03-19T13:44:33.000Z"5e2bafddb6b6c6f55861f853bd23c58e"CRC64NVMEFULL_OBJECT1112138STANDARDattachment/Belimumab_11_30_18_FDA.pdf2018-11-30T20:55:57.000Z"ce11e1c1ee3de081a17f346d6cf20309"1429779STANDARDattachment/Belimumab_12_16_2013_FDA.pdf2016-11-16T19:45:49.000Z"1b9a2b468787ece0e47e8caddc070b53"185713STANDARDattachment/Belimumab_EMA_EPAR_May_02_2014.pdf2016-11-16T19:46:02.000Z"5f803419ae8c2b56c19e8259e12d67e6"353724STANDARDattachment/Belimumbab_05_23_16.pdf2016-11-16T19:46:45.000Z"f543a4718d7de5ceb31a0a507df46a73"774156STANDARDattachment/Belinostat_11_30_18_FDA.pdf2018-11-30T21:01:59.000Z"dbb6e5a8f491d4acd92fd834737166ea"593310STANDARDattachment/Belinostat_FDA_12_7_15.pdf2016-11-16T19:46:43.000Z"7f6960a398b0788faf49cc9666658f5b"408307STANDARDattachment/Belzutifan_2022_08_31_HCSC.pdf2022-09-01T23:20:11.000Z"4f314be2946786a64cecdcf227c50cfd"1130186STANDARDattachment/Belzutifan_2025_01_21_HCSC.pdf2025-01-21T23:33:15.000Z"4d49d9c569a922e2fda6b8e67cdf74f4"781338STANDARDattachment/Belzutifan_2025_07_30_EMA.pdf2025-07-31T00:18:34.000Z"9e93d0704f887b2481a5b451db1b5c38"CRC64NVMEFULL_OBJECT538642STANDARDattachment/Belzutifan_2025_07_30_FDA.pdf2025-07-30T21:49:51.000Z"37b69dd6d210ca55281861d0cc080365"CRC64NVMEFULL_OBJECT1572576STANDARDattachment/Belzutifan_FDA_04052022.pdf2022-04-05T15:46:37.000Z"ff415a15f7d453d3892643ae07b3c643"467724STANDARDattachment/Bempedoic_acid_ezetimibe_2024_09_26_EMA.pdf2024-09-26T17:35:52.000Z"d0d7297ba52dfae785b4b79a67bb54f5"744981STANDARDattachment/Bempedoic_acid_ezetimibe_2024_09_26_FDA.pdf2024-09-26T17:18:51.000Z"243ba604bcbd162e9fd7c13a0d917bc2"764435STANDARDattachment/Benznidazole_3_30_2022.pdf2022-03-30T19:16:28.000Z"b4e19bbf077e56ce1e2e64501575926b"533564STANDARDattachment/Betaine_EMA_2023_03_21.pdf2023-03-21T14:37:03.000Z"c96da3466303f224f9ef530d00c9adb1"345418STANDARDattachment/Betaine_FDA_2023_03_15.pdf2023-03-15T16:46:21.000Z"d94748e3a781d2fa6d8fb2def481a264"276844STANDARDattachment/Betaine_HCSC_2023_03_21.pdf2023-03-21T14:37:13.000Z"2f76fdd9b34bcca58bd4dc9a20d0376b"498381STANDARDattachment/Betamethasone_Injection_4_4_2022.pdf2022-04-04T20:54:30.000Z"7900bcb6c094e38eeec1f735f2f6d19a"90216STANDARDattachment/Betamethasone_Topical_4_4_2022.pdf2022-04-04T20:59:39.000Z"b02e4769274013350b6dc464a5c275d9"153733STANDARDattachment/Bidil_FDA_label_Oct_2013.pdf2016-11-16T19:45:47.000Z"3649e4489a5b2aa7483890bb12a0e6bd"591442STANDARDattachment/Binimetinib_06_19_19_EMA.pdf2019-06-19T17:38:40.000Z"ce168a9c79f23218b251290d2671671f"900832STANDARDattachment/Binimetinib_08_08_18_FDA.pdf2018-08-09T19:18:58.000Z"543f8dd192920a6fb8050ba080a8b1b3"1044473STANDARDattachment/Binimetinib_2024_05_21_HCSC.pdf2024-05-21T17:04:23.000Z"4a9700fa242f00025a5752017ddc335b"990201STANDARDattachment/Biogeographical_group_map.jpg2018-10-12T20:09:09.000Z"a279b58396b9dc502876fa5a8aac4af4"4220783STANDARDattachment/Biogeographical_group_map_w_admix.png2023-10-27T22:06:22.000Z"abed59513a6af86c7db0715d335f4444"5742054STANDARDattachment/Biogeographical_group_map_w_admixed_populations.png2023-10-27T22:09:22.000Z"abed59513a6af86c7db0715d335f4444"5742054STANDARDattachment/Blinatumomab_12_10_18_FDA.pdf2018-12-10T19:02:33.000Z"39ae84342b65fa962c513b507af4ba4f"1375978STANDARDattachment/Blinatumomab_2022_08_04_EMA.pdf2022-08-05T00:31:20.000Z"f243e27e9ce6134dde22d6eed1a40dba"620685STANDARDattachment/Blinatumomab_2022_08_04_HCSC.pdf2022-08-05T01:17:09.000Z"7d44820109eb54fd3b753b797e5823fc"1636810STANDARDattachment/Blinatumomab_2024_05_21_EMA.pdf2024-05-21T20:39:11.000Z"089aafd2bec236b6d383eefe1ade9d8e"863382STANDARDattachment/Blinatumomab_2024_05_21_FDA.pdf2024-05-21T21:16:01.000Z"3892a228c9ee53cbf451dea9ebe1b53a"1111868STANDARDattachment/Blinatumomab_2024_05_21_HCSC.pdf2024-05-21T18:59:11.000Z"a3599c4bba21b0c67a5dbe1167bc619f"1198507STANDARDattachment/Blinatumomab_2024_10_02_FDA.pdf2024-10-02T21:39:10.000Z"7f6cf2cec37b98fee722900f1ac6eeb6"1703553STANDARDattachment/Blinatumomab_FDA_08_09_16.pdf2016-11-16T19:47:13.000Z"3d95201c3986d33185b15e67a5a85ad3"505331STANDARDattachment/Boceprevir_7_5_2017_FDA.pdf2019-03-05T22:27:47.000Z"d7e1a22650aaf7db43eb75fe68aa85bc"1272551STANDARDattachment/Boceprevir_FDA_label_Oct_17_2013.pdf2016-11-16T19:45:47.000Z"65818d6342d9e1132be667a834e1a38b"760240STANDARDattachment/Boceprevir_HCSC_05_05_15.pdf2016-11-16T19:47:06.000Z"6d1dcae8a4aa06ba8d56cb1d43917c0e"821284STANDARDattachment/Bosutinib_06_19_19_EMA.pdf2019-06-19T18:53:56.000Z"f76b53319b25ad88e7ee6b064b12bd83"568813STANDARDattachment/Bosutinib_12_10_18_FDA.pdf2018-12-10T22:29:25.000Z"9f85ff2501b33bce72bde7141df31537"1228248STANDARDattachment/Bosutinib_12_16_2013_FDA.pdf2016-11-16T19:45:49.000Z"c319ce8162ccda3cef11f1896ef474f3"340043STANDARDattachment/Bosutinib_2024_08_05_HCSC.pdf2024-08-05T18:30:34.000Z"f25184c1679a6ec8e5149dfc2c37eea4"1281312STANDARDattachment/Bosutinib_2025_01_15_FDA.pdf2025-01-15T20:10:27.000Z"48ec6ce8d8496cc1a686731b0fa45d58"1244260STANDARDattachment/Bosutinib_HCSC_05_15_15.pdf2016-11-16T19:47:07.000Z"59890d0cbe4e96f6e915cbbeff8bcf8a"833602STANDARDattachment/Bosutinib_HCSC_07_29_15.pdf2016-11-16T19:46:34.000Z"87778a0e83c1a721ccd8e920a3241b19"985225STANDARDattachment/Brentuximab_3_15_2012.pdf2016-11-16T19:45:33.000Z"90ed01ce1f73da8f0c78373694ca163a"195016STANDARDattachment/Brentuximab_Vedotin_06_19_19_EMA.pdf2019-06-19T22:12:02.000Z"97dc06a3537521b6b87cb12f199cada7"1006069STANDARDattachment/Brentuximab_Vedotin_08_29_17_FDA.pdf2017-08-29T20:38:55.000Z"894cec840b83feb2a3b4ebc2e8374f47"374801STANDARDattachment/Brentuximab_Vedotin_12_10_18_FDA.pdf2018-12-13T17:50:00.000Z"4fbfcab34b92d0f94adf2b482fdeb3cb"1670557STANDARDattachment/Brentuximab_Vedotin_20230403_FDA.pdf2023-04-03T22:24:01.000Z"711b904432c8636e5a22ff94344fd120"1091103STANDARDattachment/Brentuximab_vedotin_20230403_HCSC.pdf2023-04-03T22:36:36.000Z"7bb0b2f764dd2dddf41681598f64665d"2855993STANDARDattachment/Brentuximab_vedotin_HCSC_05_15_15.pdf2016-11-16T19:47:08.000Z"60464e9809c27ca750d9e5a2e8db7b80"751946STANDARDattachment/Brexpiprazole_02_11_26_FDA.pdf2026-02-11T22:34:42.000Z"2323983f4e4df133d2812ef9c6c33b9a"CRC64NVMEFULL_OBJECT1801791STANDARDattachment/Brexpiprazole_06_19_19_EMA.pdf2019-06-19T22:18:34.000Z"c3ed2d330641338ec1337f82f071f5e3"899975STANDARDattachment/Brexpiprazole_12_13_18_FDA.pdf2018-12-13T18:36:39.000Z"bd1c5e34ab6f28a1f677e2dd17864616"1791429STANDARDattachment/Brexpiprazole_2024_10_15_HCSC.pdf2024-10-15T22:16:02.000Z"367a9b86d23fd061bca972549e02e9a6"1282551STANDARDattachment/Brexpiprazole_FDA_08_18_16.pdf2016-11-16T19:47:26.000Z"3ceb2485a177ba2efef0ebead9d41e5b"699788STANDARDattachment/Brigatinib_06_19_19_EMA.pdf2019-06-19T22:24:49.000Z"2ed0ae0372505dbde4fac8bdc00c0935"639929STANDARDattachment/Brigatinib_08_29_17_FDA.pdf2017-08-29T20:51:33.000Z"1987809209ce30a01042d0e56051a3b4"419943STANDARDattachment/Brigatinib_2024_05_21_HCSC.pdf2024-05-22T00:49:27.000Z"e4490c2ca41e69c36308b8f9c3026bb1"1458737STANDARDattachment/Brigatinib_2024_08_02_FDA.pdf2024-08-02T23:28:49.000Z"cb5e68dd171a6ee6520621adf147fb24"316837STANDARDattachment/Brilique_EMA_EPAR_Oct_29_2013.pdf2016-11-16T19:44:28.000Z"3e270ebf04ff025915775e9a426474c6"400750STANDARDattachment/Brivaracetam_05_25_16_FDA.pdf2016-11-16T19:47:25.000Z"a29db121ea6a59eebd027d4911b92e78"1888283STANDARDattachment/Brivaracetam_06_19_19_EMA.pdf2019-06-19T22:31:20.000Z"f034099d8694fbe59dc1bd450db40e00"1359281STANDARDattachment/Brivaracetam_12_14_18_FDA.pdf2018-12-14T19:22:02.000Z"ee019f9efec85cf5d3a661f00a5f7224"1123593STANDARDattachment/Brivaracetam_2024_07_15_EMA.pdf2024-07-15T18:06:44.000Z"1fa1fe33ded002defdd01f4101a12262"1264810STANDARDattachment/Brivaracetam_2024_07_15_FDA.pdf2024-07-15T17:47:59.000Z"2b133c1553c8038e18aaaa61c2b205c7"1137686STANDARDattachment/Brivaracetam_2024_07_15_HCSC.pdf2024-07-15T18:16:01.000Z"614104cb3c591d9f1e42f328d636ca8d"681066STANDARDattachment/Budesonide_Capsule_11_30_2021.pdf2021-11-30T20:27:47.000Z"12419bd694d3a47ab29e381aba083354"152666STANDARDattachment/Budesonide_Inhaler_11_30_2021.pdf2021-11-30T20:27:31.000Z"40150fb1ae9a98d1b8a67f0dd4fe4dba"423978STANDARDattachment/Bupivacaine_2022_09_12_EMA.pdf2022-09-13T15:57:43.000Z"926ebfb54b9ae70c8b5d96bc0fab2a5c"531893STANDARDattachment/Bupivacaine_2022_09_13_HCSC.pdf2022-09-13T17:20:16.000Z"87bd327f7eabfba600164ab57b2c2185"1429729STANDARDattachment/Bupivacaine_2024_07_18_FDA.pdf2024-07-19T00:25:54.000Z"5a80d620c211e9e05cfdbb0d7257fdfb"704007STANDARDattachment/Bupivacaine_2024_07_18_HCSC.pdf2024-07-19T15:40:33.000Z"44d404641770e06af4510cd3558418fe"547760STANDARDattachment/Buprenorphine_08_31_21_FDA.pdf2021-09-02T17:44:06.000Z"c60f92b4f3dc531dec96b67a437fb3d6"1961334STANDARDattachment/Busulfan_06_07_2017_FDA.pdf2018-12-14T19:30:14.000Z"2f219adc86dce5d0447facda1c4bf064"264035STANDARDattachment/Busulfan_2025_01_15_EMA.pdf2025-01-15T20:30:31.000Z"78124c3e412903ee12c32f1ea1bd8e20"338667STANDARDattachment/Busulfan_2025_01_15_HCSC.pdf2025-01-15T20:34:26.000Z"d8f9f5d827efdef906ba10515c2671d4"840561STANDARDattachment/CA-scoring-flowchart.png2021-03-31T17:40:42.000Z"1d361f2f434c5351fc2028f3d449c22f"37977STANDARDattachment/CACNA1S_Gene_Resource_Mappings.xlsx2018-09-17T21:54:14.000Z"1c192d5e7425f23d6b8eea53af32991a"9280STANDARDattachment/CACNA1S_VIP_Summary.pdf2024-10-19T06:16:23.000Z"63615e2207a1456125373e4c50152ea1"240588STANDARDattachment/CACNA1S_allele_definition_table.xlsx2021-10-22T20:00:23.000Z"fc71db2ce8b323564875a7059c6a35dc"5212STANDARDattachment/CACNA1S_allele_functionality_reference.xlsx2021-10-12T15:23:41.000Z"5fc66d3d9316ce1f1eb6c2d1abbc9f2f"13192STANDARDattachment/CACNA1S_consult_text_and_implementation_workflow.xlsx2018-09-17T21:53:47.000Z"5f12acd730bb6311778057af438acb69"17631STANDARDattachment/CACNA1S_consult_text_and_implementation_workflow_post.xlsx2021-11-19T18:57:33.000Z"7a4604c88d46b8e3a2b4ad865011d9e7"17214STANDARDattachment/CACNA1S_frequency_table.xlsx2020-02-28T22:39:42.000Z"dc58830fd816ca27051c983cbf8e7d37"20961STANDARDattachment/CA_Levels_of_Evidence.svg2021-03-22T18:54:45.000Z"0acca2fb6735fef3e0ebc1989ccc80f4"34239STANDARDattachment/CDERElexacaftorIvacaftorTezacaftor2019.pdf2024-02-21T15:00:35.000Z"b249e5a1d920f8df2ece345a6d508cdc"6191381STANDARDattachment/CDERIvacaftor2012.pdf2024-02-21T14:37:48.000Z"d38ba99ff00d5ab273e4f7447c40962c"6470522STANDARDattachment/CDERIvacaftorTezacaftor2018.pdf2024-02-21T14:55:12.000Z"39377d993a32f1de0d7818363dcc213f"10787032STANDARDattachment/CFTR_Gene_Resource_Mappings.xlsx2018-03-23T00:02:01.000Z"676d3526621166daedf7df93a9470fb0"34914STANDARDattachment/CFTR_allele_definition_table.xlsx2025-09-16T02:40:07.000Z"48935fb35a65770ff004462cd2e9ff52"CRC64NVMEFULL_OBJECT13225STANDARDattachment/CFTR_ivacaftor_Figure1.png2016-11-16T19:46:00.000Z"50cad52909face033e95edb63df16ce2"55752STANDARDattachment/COMT_VIP_Summary.pdf2024-10-19T06:16:28.000Z"d568fc5dca0f1c9f5c60706b3f68f5a1"72545STANDARDattachment/CPIC-Members-MOU.pdf2025-11-06T22:53:12.000Z"26d11005ddd522806253fa1e960eb0a3"CRC64NVMEFULL_OBJECT16805STANDARDattachment/CPIC-Publications-MOU-Oct2013.pdf2016-11-16T19:44:29.000Z"94f2e89563e635e2d798279aa4a3c701"18662STANDARDattachment/CPIC-UGT1A1.pdf2016-11-16T19:47:21.000Z"8992b52f3f0e81466e903cad5023d93f"229607STANDARDattachment/CPIC_2C19_clopidogrel_guideline2013.pdf2016-11-16T19:44:17.000Z"0be5262a28b9223fe94cd519545bd45e"239517STANDARDattachment/CPIC_2C19_clopidogrel_supplement2013.pdf2016-11-16T19:45:07.000Z"ec8ee1bc4a69b6f878ae9f611aa9e8a4"470202STANDARDattachment/CPIC_2D6-Codeine.pdf2016-11-16T19:45:32.000Z"2cfe25924979fd61c682f169362dbfd3"154334STANDARDattachment/CPIC_2D6-Codeine_Manuscript_Final.docx2018-03-23T00:02:01.000Z"c2524d317879b6897e67d8f7ad1a44a1"116250STANDARDattachment/CPIC_2D6-Codeine_Manuscript_Final.pdf2016-11-16T19:45:32.000Z"8b97b96f43ba4ac175c53fe6468d266c"209157STANDARDattachment/CPIC_2D6-Codeine_Supplemental_Material.docx2018-03-23T00:02:02.000Z"d4fb35572dae44775f3e4928aef495d7"123058STANDARDattachment/CPIC_2D6-Codeine_Supplemental_Material.pdf2016-11-16T19:44:10.000Z"610447c13bc0ac9a0129b23c8bdd5620"555203STANDARDattachment/CPIC_2D6_Codeine_manuscript_update2014-1.pdf2016-11-16T19:46:07.000Z"7af82e7f7154eec7005b61538003eafe"1025618STANDARDattachment/CPIC_2D6_Codeine_manuscript_update2014-2.pdf2016-11-16T19:45:58.000Z"2805396879a0c4348686cad575164347"300487STANDARDattachment/CPIC_2D6_Codeine_manuscript_update2014.pdf2016-11-16T19:45:30.000Z"da6123c8ed3524ba7db432bf10e31aae"272864STANDARDattachment/CPIC_2D6_Codeine_supplement_update2014.pdf2016-11-16T19:45:48.000Z"0ec2ca080a25ffbb792802f234e58cba"160015STANDARDattachment/CPIC_2D6_Codeine_supplement_update2014_update.pdf2016-11-16T19:47:11.000Z"aec84d60b8ee7b2a127c48bb825a64ba"266230STANDARDattachment/CPIC_Abacavir_HLAB_Supplement_Update.pdf2016-11-16T19:46:37.000Z"a0cce6c3f6f9e2ea2019ac4a3bfe4f92"836634STANDARDattachment/CPIC_Abacavir_HLAB_Supplement_Update_MA.pdf2016-11-16T19:46:22.000Z"a0cce6c3f6f9e2ea2019ac4a3bfe4f92"836634STANDARDattachment/CPIC_CFTR_Ivacaftor_Accepted_Article_Preview.pdf2016-11-16T19:46:08.000Z"2d0eaea26bd6c3bf6d13b8dd8ef2b3cd"125944STANDARDattachment/CPIC_CYP2C19_voriconazole_guideline.pdf2016-12-01T22:21:12.000Z"971b29e16e0520a7bd20a34f9572a4bd"298493STANDARDattachment/CPIC_CYP2C19_voriconazole_guideline_supplement.pdf2016-12-01T19:07:01.000Z"bfe86d333e94725df1a5f939e00e0c04"628581STANDARDattachment/CPIC_CYP3A5_Tacrolimus_2015.pdf2016-11-16T19:46:58.000Z"47547be8eaaf2ceb4ab344ce74199b14"151879STANDARDattachment/CPIC_CYP3A5_Tacrolimus_guideline_2015.pdf2016-11-16T19:47:19.000Z"f861c2e577b92a3e81dee3963fdda388"629416STANDARDattachment/CPIC_CYP3A5_Tacrolimus_guideline_supplement_2015.pdf2016-11-16T19:47:20.000Z"72918a806b92cb5ce90ed113e3072cc4"2181451STANDARDattachment/CPIC_CYP3A5_Tacrolimus_supplement_2015.pdf2016-11-16T19:46:59.000Z"fe376e5c02cf37fb76ce58d03d805a14"672587STANDARDattachment/CPIC_DPYD_Fluoropyrimidine_Dosing_2013.pdf2016-11-16T19:45:19.000Z"c8461fda385ffd9d6ea5c98937e729c2"184893STANDARDattachment/CPIC_Delphi2.pdf2016-11-16T19:46:55.000Z"7127101ecd42f746831616b5838af96b"223542STANDARDattachment/CPIC_Delphi4.pdf2016-11-16T19:47:11.000Z"9624dfe1ab95de785179e6f46f93aaa8"95356STANDARDattachment/CPIC_G6PD_rasburicase_guideline_Figure_1.png2016-11-16T19:46:10.000Z"d730f5ffba3e782c38b2b1752ebdfdf9"182323STANDARDattachment/CPIC_HLA-B_Carbamazepine_Placeholder.docx2018-03-23T00:02:02.000Z"67a2916b542bf7fdd8dcd86378ff39bd"23082STANDARDattachment/CPIC_HLA-B_Carbamazepine_Supp_Placeholder.docx2018-03-23T00:02:02.000Z"8a1f020635740a2e334b61a63ecafacd"23295STANDARDattachment/CPIC_HLA-B_Carbamazepine_guidelines.pdf2016-11-16T19:45:07.000Z"93f9e247d2fe951d6f1e46a770c71c93"184728STANDARDattachment/CPIC_HLA-B_Carbamazepine_guidelines_revision_final.pdf2016-11-16T19:45:06.000Z"4b03112c0dcfcf18f38c977ac26759bd"206667STANDARDattachment/CPIC_HLA-B_Carbamazepine_supplement.pdf2016-11-16T19:45:41.000Z"684643eb364c695d6aacb2f1e7af7866"169058STANDARDattachment/CPIC_HLA-B_Carbamazepine_supplement_revised_final.pdf2016-11-16T19:45:20.000Z"8c0adb598e39f306f539073c1c5715a8"165011STANDARDattachment/CPIC_HLAB-Abacavir.pdf2016-11-16T19:44:11.000Z"d6bee370f47aab76278e26fc5a88f2cc"218509STANDARDattachment/CPIC_HLAB-Abacavir_Supplemental_Material.pdf2016-11-16T19:44:45.000Z"4083313402b2603cc2c2b898deeb0698"376343STANDARDattachment/CPIC_HLAB-Allopurinol.pdf2016-11-16T19:44:16.000Z"8899b9ebd0aec84d7e56ba927ea5ca53"250625STANDARDattachment/CPIC_HLAB-Allopurinol_Supplemental_Material.pdf2016-11-16T19:45:03.000Z"00402ee55013cadda18a7271fb78ccfc"130296STANDARDattachment/CPIC_HLAB_Abacavir_Supplement_Update.pdf2016-11-16T19:46:04.000Z"79790bac800124e5bb302e55777459f7"695530STANDARDattachment/CPIC_HLAB_Abacavir_Update.pdf2016-11-16T19:46:01.000Z"ec4797659021d3a955203a713ecfcf24"778864STANDARDattachment/CPIC_IL28B_HCV_guideline_supplement_revised_Sep_2013.pdf2016-11-16T19:45:09.000Z"d00dfdb076244f99eb5fc97e9be071a2"710068STANDARDattachment/CPIC_IL28B_HCV_guideline_supplement_revised_Sep_2013_1.pdf2016-11-16T19:46:23.000Z"7d846889aacf8d7c3c8271e384260511"490916STANDARDattachment/CPIC_IL28B_HCV_guideline_supplement_revised_Sep_2013_2.pdf2016-11-16T19:47:39.000Z"b33f6ad7dee8b70ff1764122dba38c7e"349484STANDARDattachment/CPIC_Informatics_Description_Figure_9_24_14.png2016-11-16T19:46:22.000Z"4b8bc7148433638a83732ce35a8e548a"65266STANDARDattachment/CPIC_Ivacaftor_CFTR_Figure_1.png2016-11-16T19:45:53.000Z"ee958cb825b1937e8f2a1947c2350cb5"75342STANDARDattachment/CPIC_Ivacaftor_CFTR_guideline.pdf2016-11-16T19:46:04.000Z"887eb724fbf7dffe9ef420a56cb32c28"125940STANDARDattachment/CPIC_Ivacaftor_PharmGKB_Update.pdf2016-11-16T19:46:02.000Z"8f6a86b45a8feacaa82ca5ae2f9678ba"279624STANDARDattachment/CPIC_Ivacaftor_Supplement_PharmGKB_Update.pdf2016-11-16T19:46:03.000Z"1cdfb4d98786b0c0dc44d36e8c0fd88f"751802STANDARDattachment/CPIC_Ivacaftor_Supplement_final.pdf2016-11-16T19:46:08.000Z"0662da54e43f54f6e4183e6b13fc3cbb"628795STANDARDattachment/CPIC_Ivacaftor_supplement_May_2016.pdf2016-11-16T19:47:39.000Z"f9545aeee6e85ecbaa3cdc513a4929a9"699649STANDARDattachment/CPIC_Ivacaftor_supplement_preview.pdf2016-11-16T19:46:08.000Z"1efb5c5449e28c75aa024b98f7a83a1d"628794STANDARDattachment/CPIC_MT-RNR1_Update_Final_V3.0.pdf2026-03-09T00:34:48.000Z"d44203ad9bf57d60ae415d3b88c63abe"CRC64NVMEFULL_OBJECT63875STANDARDattachment/CPIC_Members_MOU.pdf2016-11-16T19:45:56.000Z"8f765cf25d64036858b5af0b6899022f"55990STANDARDattachment/CPIC_Prioritization.svg2026-01-30T21:36:53.000Z"47f374d5329b710a26a19ddd65b3120a"CRC64NVMEFULL_OBJECT46018STANDARDattachment/CPIC_Publications_MOU.pdf2016-11-16T19:44:13.000Z"9c2745cc71acf4c761b3eb38c3453feb"88092STANDARDattachment/CPIC_Rasburicase_G6PD_Supplement.pdf2016-11-16T19:46:09.000Z"817952e22b26188cc3e12d424a7c54e5"931567STANDARDattachment/CPIC_SLCO1B1_supp_2012.pdf2016-11-16T19:46:05.000Z"5bdcb0731628d0811fc407b797949166"708558STANDARDattachment/CPIC_SOP_Feb_2013_PharmGKB.pdf2016-11-16T19:45:06.000Z"aea42ba03957e41b31e75a01887cbb24"714810STANDARDattachment/CPIC_TCAguideline2012.pdf2016-11-16T19:45:19.000Z"30e03a731f786392f362960ce1f77495"423272STANDARDattachment/CPIC_TCAsupplement2012.pdf2016-11-16T19:45:18.000Z"f0dbedfa8ee07796178b99e99951cd4d"584169STANDARDattachment/CPIC_TERMS_Summary_OCT_2015_update.pptx2018-03-23T00:02:02.000Z"12ba6ee953a51e373a06c57e87eb42d3"438821STANDARDattachment/CPIC_TPMT_SUPPLEMENT_REVISED_May_24_2011_acc_ch.pdf2016-11-16T19:45:33.000Z"f1c25ea1f3c5514366bfb93b3f35e0f5"361107STANDARDattachment/CPIC_TPMT_update.pdf2016-11-16T19:45:40.000Z"2227045c8295595b8932e15d61183e1d"456914STANDARDattachment/CPIC_TPMT_update_supp.pdf2016-11-16T19:45:05.000Z"b485fc82c003b93c1ef226965544eaeb"772988STANDARDattachment/CPIC_Term_Standardization_Project_final_terms.pdf2016-11-16T19:47:11.000Z"0bb05bf55f52e342a016cfbab5d60e75"75786STANDARDattachment/CPIC_Term_standardization_12_17_14.pdf2016-11-16T19:46:39.000Z"977c4095c9571a53a2c06d02d9c5fcb8"173447STANDARDattachment/CPIC_UGT1A1_Atazanavir.pdf2016-11-16T19:47:38.000Z"0e4148965469b13e9fcb67795c5417b6"770994STANDARDattachment/CPIC_UGT1A1_atazanavir_supplement.pdf2016-11-16T19:46:42.000Z"a00c54b272410f341bf82bacb515831d"1433781STANDARDattachment/CPIC_allopurinol_update_2015.pdf2016-11-16T19:46:32.000Z"8280a642bc07fa428144d1b892c3196b"123034STANDARDattachment/CPIC_allopurinol_update_blurb_final.docx2018-03-23T00:02:03.000Z"9e91aa697798405e7af9b0db0cb20737"40699STANDARDattachment/CPIC_allopurinol_update_supplement_2015.pdf2016-11-16T19:46:32.000Z"4fd68fb9e62a1770b0cfadc67f2ae962"1969635STANDARDattachment/CPIC_atazanavir_UGT1A1_allele_frequency.xlsx2018-03-23T00:02:03.000Z"e6976ba34f61d77e3cf2ae5d4eed51d4"58430STANDARDattachment/CPIC_email_lists.png2016-11-16T19:47:30.000Z"2616f1a029a4289cdb079da0d7b68029"90760STANDARDattachment/CPIC_guidelines_TPMT_Thiopurine_2013_update.pdf2016-11-16T19:45:04.000Z"580cb08c89a9033c88f90a27d0351f03"304404STANDARDattachment/CPIC_informatics_flow_diagram_5_1_14.png2016-11-16T19:46:15.000Z"cd3181fb354f85b95a900c03b32cdf6e"69063STANDARDattachment/CPIC_rasburicase_G6PD_Preview.pdf2016-11-16T19:45:55.000Z"10e3710b992ebde7920706e419c04f3d"273095STANDARDattachment/CPIC_slides_to_share_1062016.pptx2018-03-23T00:02:03.000Z"9363f753d210a3134fb6735e85e0026d"5031329STANDARDattachment/CPIC_slides_to_share_1062016_2.pptx2018-03-23T00:02:05.000Z"428563fa7b74413233518d16c216aaf0"5032089STANDARDattachment/CPIC_statin_guideline_figure_1.png2022-02-15T04:01:55.000Z"6d49af710ce6f7ef8dc8be43cf131d65"453263STANDARDattachment/CPIC_tacrolimus_guideline_supplement_2015.pdf2016-11-16T19:46:53.000Z"2803a8a5fc593561ee63e757b4c7c137"2187791STANDARDattachment/CPIC_term_standardization_survey_results.pdf2016-11-16T19:47:31.000Z"a6674e416734377f16f5ab9e0bdc6845"526285STANDARDattachment/CPIC_warfarin_2017_Fig_2.png2017-02-06T21:22:16.000Z"7fbff62c61cd1751c9c44d7a8c387d37"302056STANDARDattachment/CPIC_warfarin_2017_Fig_3.png2017-02-06T21:22:31.000Z"0c70a4ac0cdf0eecd425870e1114a12d"83359STANDARDattachment/CPIC_warfarin_guideline_2017_update_revised_final_1.pdf2017-02-06T20:58:33.000Z"b7527f5275d68e02c9d39a3f20c9d73b"930333STANDARDattachment/CYP1A2.pdf2022-09-16T16:04:28.000Z"7399c7889926432f4b1e06c24671a1cb"125399STANDARDattachment/CYP1A2_allele_definition_table.xlsx2025-06-16T21:56:21.000Z"be866c03fd8fdd6288067d9dc545c34b"CRC64NVMEFULL_OBJECT9238STANDARDattachment/CYP2A13_VIP_Summary.pdf2024-10-19T06:16:33.000Z"4d42564a051a5f1d0c47ad4d727b96e3"31112STANDARDattachment/CYP2A6_allele_definition_table.xlsx2024-07-09T23:18:45.000Z"b22ec0673505b19044f582c994acf3a4"11582STANDARDattachment/CYP2B6.pdf2022-09-16T16:04:39.000Z"510a2796a731605cbb836421d22dadc9"157225STANDARDattachment/CYP2B6_Diplotype_Phenotype_Table.xlsx2021-05-03T18:13:31.000Z"b3ff020c0b37b36ff99746c5d7e2fab5"205526STANDARDattachment/CYP2B6_Gene_Resource_Mappings.xlsx2019-01-23T18:04:36.000Z"aeeed8949be69863bd5821d81d95f102"9264STANDARDattachment/CYP2B6_Genotype_to_Phenotype_Translation_Template.xlsx2021-04-29T17:16:33.000Z"d399a3e2dfb358dfc8fe3141461645a1"17726STANDARDattachment/CYP2B6_Genotyping_Method_and_Data_Template.xlsx2021-04-29T17:16:44.000Z"c5ce3de68b512b54d808d33f69f9f0df"27153STANDARDattachment/CYP2B6_allele_definition_table.xlsx2025-05-28T18:00:03.000Z"4be62eca5f52b9e95e7d38b1f1e6d855"CRC64NVMEFULL_OBJECT9776STANDARDattachment/CYP2B6_allele_functionality_reference.xlsx2021-04-28T02:36:07.000Z"2d0fa70fd856d78a19c4bbe01f9d81f8"23673STANDARDattachment/CYP2B6_frequency_table.xlsx2021-05-06T06:01:39.000Z"f521fb83d8076fb4aa958bb04835a250"92122STANDARDattachment/CYP2C19.pdf2022-09-16T16:04:59.000Z"eb3ecc7a2cef04a70622e2e177fccbbb"170044STANDARDattachment/CYP2C19_Decision_Table_Vanderbilt_StJude_OhioSt_FL_UM.Revised_July_11_2013.xlsx2018-03-23T00:02:06.000Z"dc0ca39b60e65bfc8642e966266d21b0"47839STANDARDattachment/CYP2C19_Decision_Table_Vanderbilt_StJude_OhioSt_FL_UM.xls2016-11-16T19:45:05.000Z"ac53971ea0597dcb78391788831baf34"138240STANDARDattachment/CYP2C19_Decision_Table_Vanderbilt_StJude_OhioSt_FL_UM.xlsx2018-03-23T00:02:07.000Z"f4cb9c136d9f76e256773f3a1610647d"48181STANDARDattachment/CYP2C19_Diplotype_Phenotype_Table.xlsx2022-01-18T00:30:22.000Z"d5c6dcbfd386afc124ec04e6ef748df0"211935STANDARDattachment/CYP2C19_Frequency_Table_and_Legend_V1.pdf2016-11-16T19:46:24.000Z"1a5aed57c26e26d227d22d3869582a65"164734STANDARDattachment/CYP2C19_Gene_Resource_Mappings.xlsx2018-03-23T00:02:07.000Z"54f541f860a7aaee338ebc81c14b213a"37302STANDARDattachment/CYP2C19_Genotype_to_Phenotype_Translation_Template.xlsx2021-04-29T17:17:25.000Z"9fd1e7aa3d0a22520367ecf4d7c79d48"17737STANDARDattachment/CYP2C19_Genotyping_Method_and_Data_Template.xlsx2021-04-29T17:17:35.000Z"48aad8e730123104f34b76b4faf6bcec"28247STANDARDattachment/CYP2C19_SSRI_translational_table_posted.xlsx2018-03-23T00:02:07.000Z"9bf4ccd8c7594c3cd34271ab6d2b8fa4"29669STANDARDattachment/CYP2C19_allele_definition_table.xlsx2026-02-05T20:59:20.000Z"87c78cac9d95ba6500c6e972da10c13c"CRC64NVMEFULL_OBJECT9688STANDARDattachment/CYP2C19_allele_functionality_reference.xlsx2022-01-18T04:27:37.000Z"3cc003f7bc0ac4e8581ec35bc15f33f0"26428STANDARDattachment/CYP2C19_allele_genotype_reporting_template_v1.0.xlsx2020-06-14T18:57:43.000Z"8a7a565f5368f1b9526e3f79b789c37b"27794STANDARDattachment/CYP2C19_clopidogrel_140213.xlsx2018-03-23T00:02:08.000Z"12878a4ecddfd0b64b5e32234f22eadd"121856STANDARDattachment/CYP2C19_clopidogrel_140702.xlsx2018-03-23T00:02:08.000Z"dac134dc75a8468a789a0522cf4f4614"116774STANDARDattachment/CYP2C19_frequency_table.xlsx2022-01-18T00:29:36.000Z"7b6300bca9c44657ab8a6f80f7f3e480"196524STANDARDattachment/CYP2C19_frequency_table_V1_posted.xlsx2018-03-23T00:02:09.000Z"9bb58419d4162c17f82bc6cb69325840"256271STANDARDattachment/CYP2C19_genotype-phenotype_translation_template_v1.0.xlsx2020-06-14T18:57:51.000Z"e01e4b717e75b316e922d726ebc60b05"17684STANDARDattachment/CYP2C19_workflows_140213.pdf2016-11-16T19:45:59.000Z"b72cd850fd5f9481655cbac660a34f4e"337079STANDARDattachment/CYP2C8_allele_definition_table.xlsx2024-07-09T23:58:41.000Z"798d8e7e99465d67541a3a0876aea934"7192STANDARDattachment/CYP2C9.pdf2022-09-16T16:04:48.000Z"d932dc315a5b06381fc636280b4ffcc3"141871STANDARDattachment/CYP2C9_Diplotype_Phenotype_Table.xlsx2022-02-15T20:55:19.000Z"300818b86fe0554ac2de9e2f10c7e648"61165STANDARDattachment/CYP2C9_Gene_Resource_Mappings.xlsx2018-03-23T00:02:10.000Z"62883517d181fb185d1a657647c79302"35192STANDARDattachment/CYP2C9_Genotype_to_Phenotype_Translation_Template.xlsx2021-04-29T17:16:57.000Z"7be203d4b963f179b9637408b796ff7d"19600STANDARDattachment/CYP2C9_Genotyping_Method_and_Data_Template.xlsx2021-04-29T17:17:11.000Z"dc0b8e6556446735b69483ad25258361"26653STANDARDattachment/CYP2C9_allele_definition_table.xlsx2025-06-16T21:55:28.000Z"6a6e5ea8275e7c295d346ee45895b8df"CRC64NVMEFULL_OBJECT12805STANDARDattachment/CYP2C9_allele_functionality_reference.xlsx2022-02-15T20:57:01.000Z"dc437bc471e20da44b1e2819af452d94"45239STANDARDattachment/CYP2C9_frequency_table.xlsx2022-02-25T03:24:39.000Z"ef9546e792da60c360db9082c83e6844"154344STANDARDattachment/CYP2D6-Diplotype_Phenotype_Table.xlsx2020-07-01T23:49:17.000Z"bb810795e583eba7fe12116edbc4a1aa"273412STANDARDattachment/CYP2D6-codeine_look_up_table_10_23_14.xlsx2018-03-23T00:02:10.000Z"88f38648a8a1773c3a31ec42d2ffca10"44528STANDARDattachment/CYP2D6.pdf2022-09-16T16:05:08.000Z"0c2bfbfdaf3f4501136ea6d3c6c9c561"198810STANDARDattachment/CYP2D6_9_5_2013.xlsx2018-03-23T00:02:11.000Z"c22e086304281b2bb3909b9d6cca1100"196017STANDARDattachment/CYP2D6_Diplotype_Phenotype_Table.xlsx2022-03-18T18:09:37.000Z"df1c5fe2cca8ee0832ea981112ec5ab3"280084STANDARDattachment/CYP2D6_Frequency_Table_and_Legend_R3.pdf2016-11-16T19:47:30.000Z"efe26fdd9b889024957dc1c582fb019d"144253STANDARDattachment/CYP2D6_Gene_Resource_Mappings.xlsx2018-03-23T00:02:11.000Z"c47b57f47c6ded540c5f280a8a0351e2"37042STANDARDattachment/CYP2D6_Genotype_to_Phenotype_Translation_Template.xlsx2023-08-24T01:51:18.000Z"18d6f279cd7b11922412e6e57b29b0bc"21764STANDARDattachment/CYP2D6_Genotyping_Method_and_Data_Template.xlsx2023-08-24T01:41:18.000Z"185ea3698fdea9f627988dd8f8a893af"46909STANDARDattachment/CYP2D6_Literature_Table_and_Legend.pdf2016-11-16T19:46:23.000Z"d6729cec92d27906a4911562ecf7012b"1025182STANDARDattachment/CYP2D6_Literature_Table_and_Legend_version1.pdf2016-11-16T19:45:28.000Z"4e3f8883381bd1a13c6a3ce346a9be99"85219STANDARDattachment/CYP2D6_SSRI_translational_table_posted.xlsx2018-03-23T00:02:12.000Z"4dc24adee2e531c4c0c6de5058ea89c3"430436STANDARDattachment/CYP2D6_allele_definition_table.xlsx2025-05-28T23:20:42.000Z"9c932319239e0d482349e73d12b36596"CRC64NVMEFULL_OBJECT23996STANDARDattachment/CYP2D6_allele_frequency_literature_table_legend_FINAL.pdf2016-11-16T19:45:31.000Z"9e5134182f87026fbf6a553c77d970f7"49985STANDARDattachment/CYP2D6_allele_frequency_table.xlsx2018-03-23T00:02:12.000Z"13ce48afb1c9fd7492c51d144453d900"145617STANDARDattachment/CYP2D6_allele_frequency_table_R2.xlsx2018-03-23T00:02:12.000Z"1dffdfbb2bda910eefbcca7edd6687c0"305976STANDARDattachment/CYP2D6_allele_frequency_table_R3_posted.xlsx2018-03-23T00:02:13.000Z"6849f005a971644b0da2d5074cfb2eaa"356287STANDARDattachment/CYP2D6_allele_frequency_table_locked.xlsx2018-03-23T00:02:13.000Z"2a819408ba573a9f9e8d13b1f045ee5e"145719STANDARDattachment/CYP2D6_allele_functionality_reference.xlsx2022-03-18T18:09:04.000Z"818d23d4406499eec3e66b9c813fb4bf"21325STANDARDattachment/CYP2D6_allele_genotype_reporting_template_v1.0.xlsx2020-06-14T18:57:57.000Z"4f88ee5bc3f3f0142aa08e6c204c34f1"41541STANDARDattachment/CYP2D6_frequencies.xlsx2019-10-30T21:02:15.000Z"1240c4cca7ab71095cf5747f3eb010f0"589826STANDARDattachment/CYP2D6_frequency_table.xlsx2022-03-18T18:05:59.000Z"e9f3590d224668436ce945847df97ea5"338748STANDARDattachment/CYP2D6_genotype-phenotype_translation_template_v1.0.xlsx2020-06-14T18:58:04.000Z"9787420667032e174692509b267578d4"22374STANDARDattachment/CYP2E1_VIP_Summary.pdf2024-10-19T06:16:43.000Z"3aa32be1ba7b00780b5cb39bce9e8799"86395STANDARDattachment/CYP3A4.pdf2022-09-16T16:05:25.000Z"7ac5c662473209e4a5a0c48c47739798"127259STANDARDattachment/CYP3A4_VIP_Summary.pdf2024-10-19T06:16:51.000Z"d07637a25cebcf3286b8a413d1137f49"58122STANDARDattachment/CYP3A4_allele_definition_table.xlsx2025-12-08T23:49:13.000Z"4850d83b6e760335d585be48187cd646"CRC64NVMEFULL_OBJECT9281STANDARDattachment/CYP3A5.pdf2022-09-16T16:05:41.000Z"e4ed17e081526ca5435ef71b9cae9667"134972STANDARDattachment/CYP3A5_Diplotype_Phenotype_Table.xlsx2022-02-19T00:43:12.000Z"90446298c8718c98cc4faf8983b649e1"223186STANDARDattachment/CYP3A5_Gene_Resource_Mappings.xlsx2018-03-23T00:02:14.000Z"8e33fdfe45e45a9c5e877ab8724b5041"38926STANDARDattachment/CYP3A5_Genotype_to_Phenotype_Translation_Template.xlsx2021-12-08T21:45:04.000Z"8f70c2bd7f23ebe6d1106c3f13591c4f"18763STANDARDattachment/CYP3A5_Genotyping_Method_and_Data_Template.xlsx2021-12-08T21:44:50.000Z"6c8d62ea757f04920d9b526d742fb99e"27320STANDARDattachment/CYP3A5_Literature_Table.xlsx2018-03-23T00:02:14.000Z"eb65686d48bdc2b2ac11938054a75dac"69814STANDARDattachment/CYP3A5_allele_definition_table.xlsx2022-02-18T19:09:52.000Z"684bddaa8e0c2cc0109094c19b20af89"6757STANDARDattachment/CYP3A5_allele_functionality_reference.xlsx2022-02-18T23:52:17.000Z"cdf17e4a87f784a75c79b1af102c74cd"5363STANDARDattachment/CYP3A5_frequency_table.xlsx2022-02-19T00:30:28.000Z"dcba6835c00457530d9b1c6dbd88198d"34807STANDARDattachment/CYP3A5_translation_table.xlsx2018-03-23T00:02:15.000Z"265c47781dc9f182d22987259c01949d"44143STANDARDattachment/CYP4F2_Gene_Resource_Mappings.xlsx2018-03-23T00:02:15.000Z"e4f560c7d165ad12bea44f1495a184cc"33578STANDARDattachment/CYP4F2_allele_definition_table.xlsx2025-11-03T16:57:19.000Z"8ab4dba41e6ef211bef8ea5cd00cb35c"CRC64NVMEFULL_OBJECT7215STANDARDattachment/CYP4F2_allele_functionality_reference.xlsx2018-03-23T00:02:17.000Z"de19d509ef555bf0ec4583c30ad92129"9415STANDARDattachment/CYP4F2_frequency_table.xlsx2019-12-09T17:19:34.000Z"cc053bbc0b7f1e3a685276811a1023fa"30891STANDARDattachment/CabotegravirRilpivirine_FDA_2023_12_05.pdf2023-12-05T15:26:54.000Z"1d854074bf310dac8c47030b4a585298"3557381STANDARDattachment/Cabozantinib_12_14_18_FDA.pdf2018-12-14T20:39:08.000Z"7d6eea6bbe162c524cc4675669a99c75"1029154STANDARDattachment/Cabozantinib_FDA_08_17_16.pdf2016-11-16T19:47:13.000Z"5d043b55824310926091e0a36055f23e"443095STANDARDattachment/Canakinumab_3_30_2022.pdf2022-03-30T16:04:08.000Z"841facbef4a10d4f1aaa68eb4d3dc5b0"783079STANDARDattachment/Capacitabine_medec_2022_06_03_EMA.pdf2022-06-04T02:23:53.000Z"f5ab4bd8cef65981a646a1e3941f8b1b"794676STANDARDattachment/Capecitabine_06_19_19_EMA.pdf2019-06-19T22:57:58.000Z"1be1025505b6eb9db2b3cee0b4679bfe"874111STANDARDattachment/Capecitabine_12_14_18_FDA.pdf2018-12-14T20:58:25.000Z"8c7e9e659b7ad35e44ef828b287e2939"2044476STANDARDattachment/Capecitabine_20230330_HCSC.pdf2023-04-01T00:32:30.000Z"ea01637362cb5e2bd8a99d9e670656f2"1984817STANDARDattachment/Capecitabine_2025_10_08_FDA.pdf2025-10-08T17:05:47.000Z"7aff3b69330809a09122e3c5d258b814"CRC64NVMEFULL_OBJECT1694080STANDARDattachment/Capecitabine_6_27_2011.pdf2016-11-16T19:44:33.000Z"f0c539aa60841e0eec877f38b6cb4695"524137STANDARDattachment/Capecitabine_9_18_24_AEMPS.pdf2024-10-01T19:17:42.000Z"39db716ee2dd9824c2659dae6277852c"594272STANDARDattachment/Capecitabine_EMA_EPAR_03_16_16.pdf2016-11-16T19:47:24.000Z"1e99ddab1aba8d41955be986e3b95715"640540STANDARDattachment/Capecitabine_FDA_10_27_15.pdf2016-11-16T19:46:58.000Z"3be0be49bb34ecfba3ddd8d42b24c525"1095291STANDARDattachment/Capecitabine_FDA_label_Oct_18_2013.pdf2016-11-16T19:45:28.000Z"d41d8cd98f00b204e9800998ecf8427e"0STANDARDattachment/Capecitabine_HCSC_05_15_15.pdf2016-11-16T19:47:08.000Z"6f71e805c31f3a27f038b82910429717"722472STANDARDattachment/Capecitabine_PMDA_11_14_14.pdf2016-11-16T19:46:22.000Z"4072e42e36554333d8a18d9e4f8b1f1b"817609STANDARDattachment/Capivasertib_2025_01_10_EMA.pdf2025-01-10T22:58:03.000Z"d261da41a9fdafcacf0afefde517bc30"673688STANDARDattachment/Capivasertib_FDA_2024_03_04.pdf2024-03-05T13:40:36.000Z"abb26945d8a0402e7cd5911826bc6fd7"1276273STANDARDattachment/Capivasertib_HCSC_2024_03_05.pdf2024-03-05T14:47:11.000Z"47d1335667ea16707c197132943f971a"782702STANDARDattachment/Capmatinib_EMA_2023_10_11.pdf2023-10-11T15:11:47.000Z"86192cfbbf9fc4d2deb3aab02840c5cf"561472STANDARDattachment/Carbamazepine_12_14_18_FDA.pdf2018-12-14T21:18:55.000Z"bd30ea54ef16ffa4dee603e280c278fd"1593626STANDARDattachment/Carbamazepine_2024_09_18_HCSC.pdf2024-09-18T18:14:24.000Z"22546944c7df0736861df737cdc1e2e6"729818STANDARDattachment/Carbamazepine_9_17_24_AEMPS.pdf2024-09-17T19:50:59.000Z"3cb3185ce41d5e881d6ec171abf4f04a"736966STANDARDattachment/Carbamazepine_FDA_label_Oct_18_2013.pdf2016-11-16T19:45:28.000Z"3e5ce001943c111eede8940efa725c12"452417STANDARDattachment/Carbamazepine_HCSC_05_15_15.pdf2016-11-16T19:47:08.000Z"dd476ca9f3e4715a4ebc7ee64252b81a"544028STANDARDattachment/Carbamazepine_PMDA_10_03_16.pdf2016-11-16T19:47:02.000Z"4a6f0ee0a1c2db7529f6982a042b9e1e"712393STANDARDattachment/Carbamazepine_PMDA_11_14_14.pdf2016-11-16T19:47:28.000Z"5683b4304abe4b59fa8467f808c65ec8"751649STANDARDattachment/Carglumic_Acid_06_19_19_EMA.pdf2019-06-19T23:15:10.000Z"a7eccc487c6de86fd688d4234205913f"243946STANDARDattachment/Carglumic_Acid_07_13_2017_FDA.pdf2019-03-04T19:19:13.000Z"63091d7a69832f335562becfd245ea75"752823STANDARDattachment/Carglumic_Acid_12_16_2013_FDA.pdf2016-11-16T19:45:49.000Z"ac5f2acab8dc9bc81cccaaf630f5aba4"154833STANDARDattachment/Carglumic_Acid_HCSC_10_22_15.PDF2016-11-16T19:46:43.000Z"b068d97bfb9493fd7e65dea6ec81562a"460400STANDARDattachment/Carglumic_acid_2024_08_05_HCSC.pdf2024-08-05T19:17:34.000Z"d6c456615562335f953c54f146037ccf"697786STANDARDattachment/Carglumic_acid_EMA_EPAR_May_02_2014.pdf2016-11-16T19:45:57.000Z"154cf5c7daac5d72135447831c71af79"152951STANDARDattachment/Cariprazine_2025_04_15_HCSC.pdf2025-04-15T22:46:17.000Z"400e6adee8258af9c62bd89754499b94"CRC64NVMEFULL_OBJECT975594STANDARDattachment/Cariprazine_2025_07_30_EMA.pdf2025-07-31T18:05:29.000Z"2e465feb7d036962e322c99d005dff26"CRC64NVMEFULL_OBJECT668275STANDARDattachment/Cariprazine_FDA_02_12_18.pdf2018-02-13T19:20:07.000Z"4d058adbf2376cb58123aee1b7c4009c"1715034STANDARDattachment/Carisoprodol_01_07_19_FDA.pdf2019-03-04T19:19:54.000Z"46644fa938bbe0be70bae2ff50800621"679138STANDARDattachment/Carisoprodol_10_15_2013_FDA.pdf2016-11-16T19:45:10.000Z"ea27906af98714995803890110c75f2f"104694STANDARDattachment/Carisoprodol_1_3_2012.pdf2016-11-16T19:44:10.000Z"7001f4312ccfae856a3c1b19526555ff"219568STANDARDattachment/Carisoprodol_3_22_2013_FDA.pdf2016-11-16T19:45:41.000Z"b9f305dc2f672e0cc8a102f440abe066"96143STANDARDattachment/Carvedilol_01_08_19_FDA.pdf2019-03-04T19:24:17.000Z"506c802f5c450fe739597c816e4d0e70"1311159STANDARDattachment/Carvedilol_2024_07_19_HCSC.pdf2024-07-19T17:01:12.000Z"0d31a29f08dde9eec212c4f0c4c95a4e"726240STANDARDattachment/Carvedilol_8_30_11.pdf2016-11-16T19:45:34.000Z"a70d1b4bcb31564f28f24b48d83e0f23"439287STANDARDattachment/Carvedilol_HCSC_05_18_15.pdf2016-11-16T19:47:31.000Z"854469e02ac4d70f5899385ff593fc20"357585STANDARDattachment/Casimersen_FDA_10_12_2021.pdf2021-10-12T14:44:33.000Z"67830d1c4949e43fe215bfa001ca6228"442019STANDARDattachment/Cefepime_4_5_2022.pdf2022-04-05T14:35:56.000Z"67e1785c5903714ceb22671db24bf73c"486666STANDARDattachment/Ceftazidime_4_5_2022.pdf2022-04-05T20:00:38.000Z"00b0f64243f3f2391e3b88f71283fe23"827569STANDARDattachment/Ceftriaxone_05_13_2019FDA.pdf2019-05-15T17:43:23.000Z"a69fa3183b29e4869b827699a2062e90"394873STANDARDattachment/Ceftriaxone_2024_10_15_FDA.pdf2024-10-15T22:52:53.000Z"8e608c04fef8988412943a17757a2883"320487STANDARDattachment/Ceftriaxone_2024_10_15_HCSC.pdf2024-10-15T22:38:10.000Z"23b830b79a247f536c3eb38864ef658c"1097178STANDARDattachment/Celecoxib_01_08_19_FDA.pdf2019-03-04T19:25:10.000Z"aa9149b5b30bbe6ac8bb25a8fb51ccfa"1393194STANDARDattachment/Celecoxib_10_1_24_AEMPS.pdf2024-10-01T19:29:15.000Z"4adeb162dbe7f0ac668715a4e4ace4f8"502282STANDARDattachment/Celecoxib_2024_07_19_HCSC.pdf2024-07-19T17:22:30.000Z"2dc24873b8c9a589018f4ae122985950"996318STANDARDattachment/Celecoxib_Elyxyb_2025_07_03_FDA.pdf2025-07-03T20:51:45.000Z"251a97512d98b43a18e98dfdafd052b6"CRC64NVMEFULL_OBJECT828388STANDARDattachment/Celecoxib_HCSC_05_19_15.pdf2016-11-16T19:46:27.000Z"cc80d68da430cca832776aaebe762e70"851181STANDARDattachment/Celecoxib_PMDA_08_18_16.pdf2016-11-16T19:47:42.000Z"13a833dd6e69defc62438bed76d8ffc4"581687STANDARDattachment/Celecoxib_PMDA_11_14_14.pdf2016-11-16T19:46:49.000Z"fa84199510ce1f2f75c7b0a49d497fe9"637894STANDARDattachment/Ceritinib_01_08_19_FDA.pdf2019-03-04T19:25:53.000Z"154987d76f3676d5f162a7bcb0079672"1297515STANDARDattachment/Ceritinib_02_27_15.pdf2016-11-16T19:47:08.000Z"b65ca6027d84279d90df3573585ba7d3"487690STANDARDattachment/Ceritinib_06_19_19_EMA.pdf2019-06-19T23:24:41.000Z"6e35716d8f10e8c7b20b3a343a21f729"845983STANDARDattachment/Ceritinib_2024_12_02_HCSC.pdf2024-12-02T19:26:13.000Z"84cab178881e8cfd48812e1ffcad6a82"1587164STANDARDattachment/Ceritinib_EMA_EPAR_09_17_15.pdf2016-11-16T19:47:37.000Z"67deddbfb92da9c94c3aaf33cf44f636"549730STANDARDattachment/Ceritinib_HCSC_10_22_15.pdf2016-11-16T19:47:38.000Z"903be0e3df8240eda928b3888c2e6fcb"912273STANDARDattachment/Cerliponase_Alfa_06_19_19_EMA.pdf2019-06-19T23:30:24.000Z"d0f6720a1ffb3b1472ef9ed8e031707a"615718STANDARDattachment/Cerliponase_Alfa_08_29_17_FDA.pdf2017-08-29T21:14:05.000Z"c7490b9039376e32d38773daf933f7da"782241STANDARDattachment/Cerliponase_alfa_2024_08_05_HCSC.pdf2024-08-05T20:19:49.000Z"ca0ce9b07c7107449f8e3af4ab9708d9"664675STANDARDattachment/Cetuximab_01_08_19_FDA.pdf2019-03-04T19:26:37.000Z"79e2675dcb59a25cbf9536e68571d6f7"1316263STANDARDattachment/Cetuximab_03_15_17_FDA.pdf2017-03-15T18:50:51.000Z"3b69468aa3994dfd7d3f03253ba40d4a"661281STANDARDattachment/Cetuximab_06_20_19_EMA.pdf2019-06-20T17:38:45.000Z"e89c3e65a343b4c13496526eff3d0a74"1089404STANDARDattachment/Cetuximab_10_17_13.pdf2016-11-16T19:45:29.000Z"36e26515430f989f59e39a1a6095321c"357593STANDARDattachment/Cetuximab_2025_01_16_EMA.pdf2025-01-16T19:18:45.000Z"a393e62eb6ca67be76d5b706088ca8a7"285108STANDARDattachment/Cetuximab_2025_01_16_HCSC.pdf2025-01-16T21:42:41.000Z"7e459fa40b9e6bf8eb7ba6ed0b7cf223"2016263STANDARDattachment/Cetuximab_5_11_2012.pdf2016-11-16T19:45:13.000Z"011914f50e477d62440a3f71c28f1139"495505STANDARDattachment/Cetuximab_FDA_04052022.pdf2022-04-05T17:22:24.000Z"88b1238d43c33d722ce62a49b61e830e"789579STANDARDattachment/Cetuximab_HCSC_05_20_15.pdf2016-11-16T19:46:39.000Z"35853e7817697e36559f67a7bade9ca7"1593042STANDARDattachment/Cetuximab_PMDA_08_22_16.pdf2016-11-16T19:47:14.000Z"ce76f3504a40025fb90865e410e27229"660761STANDARDattachment/Cetuximab_PMDA_11_17_14.pdf2016-11-16T19:47:06.000Z"cb5910cc082c13a2d6407882b5d5f773"603684STANDARDattachment/Cevimeline_07_13_2017_FDA.pdf2019-03-05T22:31:07.000Z"7cdc7ea900e060ba7247818e7553beff"305523STANDARDattachment/Cevimeline_8_31_11.pdf2016-11-16T19:44:33.000Z"d0b0460a356efd7ed634ce07ae6319cc"128541STANDARDattachment/Cevimeline_8_31_11_1.pdf2016-11-16T19:44:24.000Z"f7aacda0204904c30b172265ee87a316"133911STANDARDattachment/Chlordiazepoxide_and_Amitriptyline_1_5_2012.pdf2016-11-16T19:44:10.000Z"5882bc76ac6f1e9f2c4052e3f5e5547f"340798STANDARDattachment/Chloroprocaine_05_13_2019FDA.pdf2019-05-15T17:44:00.000Z"8f0e640776c7807b73f094e3b6abb697"188655STANDARDattachment/Chloroprocaine_2025_04_08_HCSC.pdf2025-04-08T21:02:13.000Z"fe09ac6987eb8bf3c3437c398b9c9ac4"CRC64NVMEFULL_OBJECT686862STANDARDattachment/Chloroquine_01_08_19_FDA.pdf2019-03-04T19:27:25.000Z"a833ea9fde8358626c93e7ed845d46cb"234515STANDARDattachment/Chloroquine_06_28_11.pdf2016-11-16T19:44:33.000Z"16f64b50e5da6c925b5a794131445c2e"84248STANDARDattachment/Chloroquine_12_2_2022.pdf2022-12-02T21:42:11.000Z"746f21bff44e5bfa5a433341f97eb7c7"411177STANDARDattachment/Chlorpropamide_07_13_2017_FDA.pdf2019-03-04T19:28:10.000Z"7c8982b4b5250a98b8f8303bef0def50"166878STANDARDattachment/Chlorpropamide_12_16_2013_FDA.pdf2016-11-16T19:45:50.000Z"ca4d5435935db7a26e129c7736ea378b"52324STANDARDattachment/Chlorpropamide_HCSC_05_20_15.pdf2016-11-16T19:46:26.000Z"8ffcc49fcff8b5226de14498a33c0507"124602STANDARDattachment/Cholic_Acid_07_13_2017_FDA.pdf2019-03-04T19:28:50.000Z"1a7cb03d2773f8970855194c36a5a07a"367562STANDARDattachment/Cholic_Acid_FDA_08_18_16.pdf2016-11-16T19:46:45.000Z"7b863b2abde9a24310a4d7d725a6475c"363780STANDARDattachment/Cholic_Acid_Kolbam_06_20_19_EMA.pdf2019-06-20T18:09:22.000Z"0162afa15875509c631d89401f310ab8"857476STANDARDattachment/Cholic_Acid_Orphacol_06_20_19_EMA.pdf2019-06-20T18:09:47.000Z"94b2e012f882711714946e8477e52c76"798876STANDARDattachment/Cidofovir_4_29_2022.pdf2022-04-29T19:24:58.000Z"a47e3c62de69e28f0b1750fb90b15b1a"547776STANDARDattachment/Cipro_5_18_2022.pdf2022-05-18T18:01:54.000Z"b2f961fdc844fff753d490b3cd489351"813502STANDARDattachment/Ciprofloxacin_2022_04_28_FDA.pdf2022-04-28T23:20:55.000Z"930c67cb6beaca0eeb1990029e8aa82c"90572STANDARDattachment/Cisplatin_01_30_12.pdf2016-11-16T19:45:33.000Z"d5ac676ff88b2f534586c00e67d841fd"149856STANDARDattachment/Cisplatin_07_13_2017_FDA.pdf2019-03-04T19:29:59.000Z"98c00ed4f3623c5354ff171612569629"211186STANDARDattachment/Cisplatin_2024_07_26_FDA.pdf2024-07-27T00:05:36.000Z"5bf7d1e323b97565ca0cc10f26c350ef"87935STANDARDattachment/Cisplatin_2024_10_16_HCSC.pdf2024-10-16T20:20:37.000Z"0e6e91ca61517f2ccf171b0ed442b954"607285STANDARDattachment/Citalopram_01_09_19_FDA.pdf2019-03-04T19:30:34.000Z"7aa016d7934986a58e1550b7995c952d"877988STANDARDattachment/Citalopram_10_17_13.pdf2016-11-16T19:45:25.000Z"2aa669070a3fe4d7a0cd04b6a297680f"528292STANDARDattachment/Citalopram_2024_07_19_HCSC.pdf2024-07-19T21:48:57.000Z"19f46453f5de25904c6eac63a6553b99"615631STANDARDattachment/Citalopram_5_8_2012.pdf2016-11-16T19:45:00.000Z"f0750a1513033ca804ea75556f573dae"309664STANDARDattachment/Citalopram_9_17_24_AEMPS.pdf2024-09-17T19:55:50.000Z"34955c586f638af9d8c9305b15e94910"412345STANDARDattachment/Citalopram_HCSC_05_20_15.pdf2016-11-16T19:46:27.000Z"ae65fb7629b63c64691709477db4145e"528905STANDARDattachment/Cladribine_12_7_2022.pdf2022-12-07T20:47:15.000Z"5f0129a97aa4e6ce74d32b606cbbc063"755884STANDARDattachment/ClinPGx_Training_Exercises.zip2025-07-09T20:44:44.000Z"7830ca8e80624e93a65005dba4f6e986"CRC64NVMEFULL_OBJECT707506STANDARDattachment/Clindamycin_4_29_2022.pdf2022-04-29T19:59:06.000Z"a64a545abb6fb47cb142db56f34d047a"318018STANDARDattachment/Clobazam_01_09_19_FDA.pdf2019-03-04T19:32:42.000Z"a09fabef4ff4715f9bad8edf96f50dce"2066734STANDARDattachment/Clobazam_2024_10_16_HCSC.pdf2024-10-16T20:41:10.000Z"4be612553d0e61baf16e192eb7cf0912"1266209STANDARDattachment/Clobazam_5_8_2012.pdf2016-11-16T19:44:46.000Z"a4c71d4371868f527df8bb0133308585"803077STANDARDattachment/Clomiphene_5_8_2012.pdf2016-11-16T19:44:46.000Z"7b97a71b890255baf2b2a83c53778e4e"142308STANDARDattachment/Clomipramine_01_09_19_FDA.pdf2019-03-04T20:12:48.000Z"00afcf7a3e13011534bf7077e05d6b45"871199STANDARDattachment/Clomipramine_10_1_24_AEMPS.pdf2024-10-01T19:32:27.000Z"b7b5e9ff6d5eadaf23e2a872ab861225"278391STANDARDattachment/Clomipramine_2025_04_16_HCSC.pdf2025-04-16T19:41:52.000Z"b0b13dbb19a0c645a24dc1bc37842005"CRC64NVMEFULL_OBJECT736416STANDARDattachment/Clomipramine_5_8_2012.pdf2016-11-16T19:45:13.000Z"e2d73b2e7a3fc4e5eaadb1d31747cd00"472092STANDARDattachment/Clonidine_Patch_4_26_2022.pdf2022-04-26T18:05:46.000Z"bda825ba5d6c80ed5c999291363e6775"614238STANDARDattachment/Clonidine_Tablet_4_26_2022.pdf2022-04-26T18:05:57.000Z"668ad29bf7162bd463a919f0a9b3f113"542184STANDARDattachment/Clopidogrel_06_20_19_EMA.pdf2019-06-20T18:22:45.000Z"5eed985235d9501d4671c8f2ec899200"569536STANDARDattachment/Clopidogrel_07_14_2017_FDA.pdf2019-03-04T20:13:26.000Z"558b4445eb68452556a666097e3f1dc5"1275992STANDARDattachment/Clopidogrel_10_15_13.pdf2016-11-16T19:44:24.000Z"176436d3a339c102a33f2c3adc8e10d3"813372STANDARDattachment/Clopidogrel_10_1_24_AEMPS.pdf2024-10-01T19:43:23.000Z"07a04f752c3baabc0624c0353e71d967"499594STANDARDattachment/Clopidogrel_2024_07_15_EMA.pdf2024-07-18T00:08:33.000Z"24e0faaecd69a76b0e382f312306445b"660901STANDARDattachment/Clopidogrel_2024_07_15_FDA.pdf2024-07-17T23:18:58.000Z"63635505c96da9d9404c765d68d7fe71"663727STANDARDattachment/Clopidogrel_2024_07_15_HCSC.pdf2024-07-17T17:48:14.000Z"d88d158a3cc686394855a15a6bb62be6"1973283STANDARDattachment/Clopidogrel_Dosing_Table.png2016-11-16T19:47:00.000Z"a8b8c180bd20faa7801700d2a2c90fda"745592STANDARDattachment/Clopidogrel_EMA_EPAR_10_08_12.pdf2016-11-16T19:45:39.000Z"26dc7db2c3882a657e7a6cf7a6191c87"131232STANDARDattachment/Clopidogrel_FDA_02_02_17.pdf2017-02-02T22:46:00.000Z"4da2dcaf019e04451e6a0efd825fe27e"543624STANDARDattachment/Clopidogrel_HCSC_05_21_15.pdf2016-11-16T19:47:31.000Z"b1d6cc9840700c05d919bb79da801661"1422794STANDARDattachment/Clopidogrel_PMDA_10_04_16.pdf2016-11-16T19:47:15.000Z"e7334f98e706054f2e7c98e77b418e91"670701STANDARDattachment/Clopidogrel_PMDA_11_17_14.pdf2016-11-16T19:46:50.000Z"829198b334faa6b5ef4aba7cedf28b86"522910STANDARDattachment/Clozapine_01_09_19_FDA.pdf2019-03-04T20:14:44.000Z"67a72f15d842a7d63b5c2b0c81f68c93"1414111STANDARDattachment/Clozapine_2024_10_16_HCSC.pdf2024-10-16T21:16:47.000Z"7a50146fb2f28784139ef19424bbb7c2"1059349STANDARDattachment/Clozapine_8_31_11.pdf2016-11-16T19:44:33.000Z"e6f0c42502d003b6508d9955f3aecff6"291734STANDARDattachment/Cobimetinib_06_20_19_EMA.pdf2019-06-20T18:32:57.000Z"3f73923e873e5a29cc6811910eaee085"765636STANDARDattachment/Cobimetinib_07_19_17_FDA.pdf2019-03-04T20:15:02.000Z"19f267810994774989f9b06c911ae222"569674STANDARDattachment/Cobimetinib_2024_05_22_HCSC.pdf2024-05-22T17:47:53.000Z"23324469313204dccb37f7139613d053"751189STANDARDattachment/Cobimetinib_FDA_08_17_16.pdf2016-11-16T19:47:01.000Z"20c860d255a28384f9765a8912fa6544"565443STANDARDattachment/CodeineCYP2D6.CPIC.Video.pdf2016-12-09T19:00:54.000Z"1a93ce819a75db13a9212566cdf0245e"91273STANDARDattachment/Codeine_01_09_19_FDA.pdf2019-03-04T20:15:34.000Z"09899a97b5368da2a0f81aec02aa5e15"1938180STANDARDattachment/Codeine_10_11_13.pdf2016-11-16T19:45:22.000Z"4c1357af1f7a39d870c81320ba130a77"203047STANDARDattachment/Codeine_10_1_24_AEMPS.pdf2024-10-01T19:47:26.000Z"379a93dad1d0aa57b7ad96b1795063f2"292417STANDARDattachment/Codeine_2024_07_19_HCSC.pdf2024-07-19T22:20:15.000Z"39d5133e825cabe77e5256cb11bf3040"692872STANDARDattachment/Codeine_2_15_12.pdf2016-11-16T19:44:11.000Z"b1fad8be8a2dcd72b1abeee23504c577"123405STANDARDattachment/Codeine_FDA_05_01_17.pdf2017-05-02T00:11:32.000Z"fc2619b6ce6ff27a683add1c0834cc62"481289STANDARDattachment/Codeine_HCSC_05_21_15.pdf2016-11-16T19:47:31.000Z"6259fae92916f1ed95d1a214114a406c"287840STANDARDattachment/Codeine_PMDA_08_18_16.pdf2016-11-16T19:47:14.000Z"e0d11c9dd8c673a9d1cd43293add9bc9"491671STANDARDattachment/Cosibelimab-ipdl_2025_05_14_FDA.pdf2025-05-14T23:58:33.000Z"345bcad13cc3e6324164326032936f87"CRC64NVMEFULL_OBJECT1016423STANDARDattachment/Crizotinib_01_10_19_FDA.pdf2019-03-04T20:16:08.000Z"d53ce2f75dc3184df5caca8f9a6e993d"1081235STANDARDattachment/Crizotinib_06_20_19_EMA.pdf2019-06-20T18:43:14.000Z"f46c3ef97051e8da69c9289e31516c01"823697STANDARDattachment/Crizotinib_10_17_13.pdf2016-11-16T19:45:25.000Z"40c9d7cc1c97195371947ccb34a8d770"288480STANDARDattachment/Crizotinib_2024_09_10_HCSC.pdf2024-09-10T19:47:50.000Z"4df0ff86809e06eee0fcaceb4a4cd675"925774STANDARDattachment/Crizotinib_3_16_12.pdf2016-11-16T19:44:11.000Z"946809fe86de6415006afed5f474702b"317205STANDARDattachment/Crizotinib_FDA_03_15_17.pdf2017-03-15T19:06:03.000Z"f4726b67b98b7f31d5226988f4216982"533115STANDARDattachment/Crizotinib_HCSC_05_21_15.pdf2016-11-16T19:47:32.000Z"53ab0d37277ab3c599f0afc349041c8c"865420STANDARDattachment/Crizotinib_PMDA_10_04_16.pdf2016-11-16T19:47:15.000Z"78ff6f692f04b67d2da551ea21cd9e6e"624332STANDARDattachment/Crizotinib_PMDA_11_17_14.pdf2016-11-16T19:46:51.000Z"a590ae0b521174381f9d78b9be11fb37"755483STANDARDattachment/Cyclophosphamide_11_30_2022.pdf2022-11-30T21:41:28.000Z"ebb5710a5ee0988f3ac993a1ec768556"3922905STANDARDattachment/Cyclosporine_7_19_2022.pdf2022-07-22T20:06:05.000Z"c110ed4edeb002b07414f3375a1f5a89"4652331STANDARDattachment/Cytarabine_7_25_2022.pdf2022-07-25T20:11:57.000Z"e08a75778e7883dde65d8bd4105311fc"502186STANDARDattachment/DPWG_ABCG2_allopurinol_7255-7256_03072024.pdf2025-05-16T18:56:52.000Z"a2ef50602b02c580f05a908e70354125"CRC64NVMEFULL_OBJECT355028STANDARDattachment/DPWG_Acenocoumarol_and_phenprocoumon_algorithm_English_2018.xlsx2024-03-19T19:09:47.000Z"714e369b130494212e154e01ff004e1a"85512STANDARDattachment/DPWG_August_2019.pdf2019-10-02T23:46:31.000Z"16bd44f40e14712d766b734227aeb1ff"911463STANDARDattachment/DPWG_August_2020.pdf2020-08-31T17:48:49.000Z"d38e55cdb968272e3601b3052b34ddac"5351643STANDARDattachment/DPWG_COMT_methylphenidate_6432-6433.pdf2024-03-08T02:41:34.000Z"44f00f0d130e79c00a8dcfc723bf7e47"287234STANDARDattachment/DPWG_CYP1A2_clozapine_4640-to-4645.pdf2024-03-08T02:27:52.000Z"cd16be1ba76e41e9fc6e8262c9cb8103"421346STANDARDattachment/DPWG_CYP1A2_olanzapine_4646-to-4651.pdf2024-03-08T02:28:43.000Z"e4976f14a147c967e3ee482ea6b8cc63"352944STANDARDattachment/DPWG_CYP2B6_efavirenz_4754-4755-and-6928-to-6930.pdf.pdf2024-03-08T02:31:14.000Z"c3dd0375bbc369af52cdc48aad81376e"677471STANDARDattachment/DPWG_CYP2C19-mavacamten_7744-7746.pdf2025-09-08T22:37:03.000Z"2942b14b33e6a9b0a1ac69c00a513fdf"CRC64NVMEFULL_OBJECT197738STANDARDattachment/DPWG_CYP2C19_amitriptyline_7024-to-7026.pdf2024-03-08T02:45:26.000Z"c702d07cf7845347c7e66368f6d3bbba"226069STANDARDattachment/DPWG_CYP2C19_citalopram_4195-to-4197.pdf2024-03-08T02:27:03.000Z"60abcfd1cb82512724c1e105abf7d73d"176211STANDARDattachment/DPWG_CYP2C19_clomipramine_7027-to-7029.pdf2024-03-08T02:46:10.000Z"efd0a1da6d92e2bbd28cad40cbc450b8"215807STANDARDattachment/DPWG_CYP2C19_clomipramine_7027-to-7029_downloaded_111125.pdf2025-11-11T20:12:08.000Z"fe4add831a91ffb7981c0d8a01d13158"CRC64NVMEFULL_OBJECT231596STANDARDattachment/DPWG_CYP2C19_clopidogrel_2548-2549-2550.pdf2024-03-08T02:05:15.000Z"58c73c517b2989f8d9256c56426d0422"778906STANDARDattachment/DPWG_CYP2C19_doxepine_7021-to-7023.pdf2024-03-08T02:44:38.000Z"c531efed9b97c020cbc7188eefc65601"168275STANDARDattachment/DPWG_CYP2C19_escitalopram_1820-to-1822.pdf2024-03-08T01:17:07.000Z"fa612562c19f42bdefce41e9f822d91c"308771STANDARDattachment/DPWG_CYP2C19_esomeprazole_1824-to-1826.pdf2024-03-08T01:18:03.000Z"80cabd81b1cbc35c23d70a63c4d2f758"186085STANDARDattachment/DPWG_CYP2C19_fluvoxamine_3509-to-3511.pdf2024-03-08T02:11:56.000Z"33fb26730e309769deafc88286f9fdae"123381STANDARDattachment/DPWG_CYP2C19_imipramine_1913-to-1915.pdf2024-03-08T01:36:10.000Z"097169432caaf3dd4a25ffb025688906"203805STANDARDattachment/DPWG_CYP2C19_lansoprazole_1831-to-1833.pdf2024-03-08T01:19:19.000Z"eb5e4b5c4a08b7a345c2a70edb04be7e"270108STANDARDattachment/DPWG_CYP2C19_lansoprazole_2502-2504_downloaded_020926.pdf2026-02-09T19:59:28.000Z"9220d3c7b3b722edcdaca7c7d857c511"CRC64NVMEFULL_OBJECT250531STANDARDattachment/DPWG_CYP2C19_mavacamten_7744-to-7746.pdf2024-03-08T02:56:59.000Z"06346d8345d769281c14211e23ce9663"274984STANDARDattachment/DPWG_CYP2C19_mirtazapine_3506-to-3508.pdf2024-03-08T02:11:07.000Z"e02ff27b4a77ea1bf1c13f5a6e6a5e6f"120658STANDARDattachment/DPWG_CYP2C19_moclobemide_1991-to-1993.pdf2024-03-08T01:38:25.000Z"b97fb1d7b86e4640b0e42935304f65c3"112989STANDARDattachment/DPWG_CYP2C19_omeprazole_1839-to-1841.pdf2024-03-08T01:20:47.000Z"77c8df43a84e991cad5351bbbc50a363"274383STANDARDattachment/DPWG_CYP2C19_omeprazole_2505-2507_downloaded_020926.pdf2026-02-09T20:33:26.000Z"d6717919bcb7350e0c18cda906b1198e"CRC64NVMEFULL_OBJECT317604STANDARDattachment/DPWG_CYP2C19_pantoprazole_1847-to-1849.pdf2024-03-08T01:21:38.000Z"fdf26c63493a06797a600ccd8a68c15f"240236STANDARDattachment/DPWG_CYP2C19_pantoprazole_2508-2510_downloaded_020926.pdf2026-02-09T20:45:28.000Z"24e7edb66e462978c25e77b22e92c0ad"CRC64NVMEFULL_OBJECT235862STANDARDattachment/DPWG_CYP2C19_prasugrel_2545-2546-2547.pdf2024-03-08T02:04:26.000Z"4489d29c9915b38c4d710f7e571043bf"193593STANDARDattachment/DPWG_CYP2C19_rabeprazole_1856-to-1858.pdf2024-03-08T01:22:32.000Z"85bf024e190a497eb1cb6081ca024e5c"197080STANDARDattachment/DPWG_CYP2C19_sertraline_2008-to-2010.pdf2024-03-08T01:41:10.000Z"17ecf6a64c17e893f723c33e00a7dfcb"184162STANDARDattachment/DPWG_CYP2C19_ticagrelor_3515-to-3517.pdf2024-03-08T02:23:32.000Z"408812c37ab8498cec6af892428fa1c8"157935STANDARDattachment/DPWG_CYP2C19_voriconazole_1683-to-1685.pdf2024-03-08T01:15:00.000Z"0e9477be537d6d7ff43a693758fe4f85"783102STANDARDattachment/DPWG_CYP2C9_050522.pdf2025-04-24T20:19:25.000Z"0818d8907f3023b54cb126c1e28a4a46"CRC64NVMEFULL_OBJECT126093STANDARDattachment/DPWG_CYP2C9_acenocoumarol_1863-to-1869.pdf2024-03-08T01:23:32.000Z"088e03560114884c45062a728ddfcb5b"531052STANDARDattachment/DPWG_CYP2C9_glibenclamide_1877-to-1883.pdf2024-03-08T01:26:25.000Z"6b50cd1557495382e095672cacbec90f"170707STANDARDattachment/DPWG_CYP2C9_gliclazide_1884-to-1890.pdf2024-03-08T01:29:22.000Z"8d9c5a39ae5a5a956f0117366cf00cd1"149074STANDARDattachment/DPWG_CYP2C9_glimepiride_1891-to-1897.pdf2024-03-08T01:30:13.000Z"4a6647a30da06a2cd9156a197e6ec063"180264STANDARDattachment/DPWG_CYP2C9_phenprocoumon_1870-to-1876.pdf2024-03-08T01:24:57.000Z"7699e1d45c7937178c7dc83cfe13d79e"263014STANDARDattachment/DPWG_CYP2C9_phenytoin_1676-to-1682.pdf2024-03-08T01:13:51.000Z"2c094bba756372163d89fd56bcd68b00"536900STANDARDattachment/DPWG_CYP2C9_siponimod_7160-to-7166.pdf2024-03-08T02:50:25.000Z"d454f56001f914f6b999d56ff977c79c"318334STANDARDattachment/DPWG_CYP2C9_tolbutamide_1898-to-1904.pdf2024-03-08T01:31:05.000Z"d6101ad77b721d8c5b53c37839fce88d"180585STANDARDattachment/DPWG_CYP2C9_warfarin_6228-to-6234.pdf2024-03-08T02:37:50.000Z"947708bdff50d11e1dd2d2bdbdf932dd"265217STANDARDattachment/DPWG_CYP2D6-eliglustat_5704-6.pdf2025-09-08T21:48:23.000Z"80ee6ecf7937ec4f8f3f1b8070371170"CRC64NVMEFULL_OBJECT340527STANDARDattachment/DPWG_CYP2D6_amiodarone_2542-2543-2544.pdf2024-03-08T02:02:47.000Z"2332b6d090aec142bf0d872ff801c6f7"85374STANDARDattachment/DPWG_CYP2D6_amitriptyline_1920-1921-1922.pdf2024-03-08T01:37:28.000Z"78c8fa095c91ddc95a323f3de386da40"221244STANDARDattachment/DPWG_CYP2D6_amitriptyline_2569-2571_downloaded_111125.pdf2025-11-11T22:48:10.000Z"c9f5320c2ad954d04249e7b9cf8f679a"CRC64NVMEFULL_OBJECT362794STANDARDattachment/DPWG_CYP2D6_aripiprazole_1541-1542-1543.pdf2024-03-08T00:55:34.000Z"26787dbe1c8386d39da7a2d926094326"425067STANDARDattachment/DPWG_CYP2D6_aripiprazole_1541-1542-1543_downloaded_020926.pdf2026-02-09T16:47:44.000Z"c4ffa0b264f04ed7cdb729643e7b8b29"CRC64NVMEFULL_OBJECT255004STANDARDattachment/DPWG_CYP2D6_atenolol_2453-2454-2455.pdf2024-03-08T01:55:01.000Z"00a2a51dd3a6196add104b071d7e06e0"122691STANDARDattachment/DPWG_CYP2D6_atomoxetine_1598-1599-1600.pdf2024-03-08T01:10:35.000Z"295405bf37c2025bf3682bde5a6915f7"441561STANDARDattachment/DPWG_CYP2D6_bisoprolol_2456-2457-2458.pdf2024-03-08T01:56:31.000Z"2c1e88e3ad9f5cb98f8659114bf87241"141260STANDARDattachment/DPWG_CYP2D6_brexpiprazole_7046-7047-7048.pdf2024-03-08T02:48:37.000Z"ac553d02ec9bcae4257e348d86d03411"255237STANDARDattachment/DPWG_CYP2D6_carvedilol_2344-2345-2346.pdf2024-03-08T01:43:49.000Z"a27b48361b9fa51ed34b5e59fa8172fa"260129STANDARDattachment/DPWG_CYP2D6_citalopram_escitalopram_1998-1999-2000.pdf2024-03-08T01:39:18.000Z"819967d4afd2c2931c6dc5f45c07a011"186635STANDARDattachment/DPWG_CYP2D6_clomipramine_1480-1481-1482.pdf2024-03-08T00:07:37.000Z"373956718e1284e686104d3da560d1de"170958STANDARDattachment/DPWG_CYP2D6_clomipramine_2373-2375_downloaded_111125.pdf2025-11-11T21:11:36.000Z"642909579372fe8ea77c2d975d0c6c1d"CRC64NVMEFULL_OBJECT269969STANDARDattachment/DPWG_CYP2D6_clonidine_2530-2531-2532.pdf2024-03-08T01:58:29.000Z"b960d0dc6dd1e4f557e85d49b327cb4f"125251STANDARDattachment/DPWG_CYP2D6_clozapine_1529-1530-1531.pdf2024-03-08T00:10:08.000Z"8dcd3c74e0dde0fce85d00f184a64ec2"212354STANDARDattachment/DPWG_CYP2D6_codeine_1583-1584-1585.pdf2024-03-08T01:05:11.000Z"22e1099872d331bca57d5daa10f3edda"271589STANDARDattachment/DPWG_CYP2D6_disopyramide_2536-2537-2538.pdf2024-03-08T02:00:19.000Z"fa60e809e9e76e11b1ed24edc4ecc61a"90277STANDARDattachment/DPWG_CYP2D6_doxepin_2015-2016-2017.pdf2024-03-08T01:42:03.000Z"a440728893f044d97b0182d6cc8be810"127601STANDARDattachment/DPWG_CYP2D6_doxepin_2596-2598_downloaded_111125.pdf2025-11-11T21:58:31.000Z"5bd338f31965fe35f4d14a2c136f96cc"CRC64NVMEFULL_OBJECT188544STANDARDattachment/DPWG_CYP2D6_duloxetine_1673-1674-1675.pdf2024-03-08T01:12:44.000Z"d6f98ff52cc055b7637ea50c680c774d"185259STANDARDattachment/DPWG_CYP2D6_eliglustat_6137-6138-6139.pdf2024-03-08T02:36:44.000Z"f3c635b5a414fd7d29b62448a3889a8c"351979STANDARDattachment/DPWG_CYP2D6_flecainide_1592-1593-1594.pdf2024-03-08T01:08:20.000Z"c49b45847ab454057173ab9dd9f1b5a9"223608STANDARDattachment/DPWG_CYP2D6_fluoxetine_5996-5997-5998.pdf2024-03-08T02:35:52.000Z"857f8b8842b673ec9e850f61ca4b3796"131235STANDARDattachment/DPWG_CYP2D6_flupentixol_1532-1533-1534.pdf2024-03-08T00:49:44.000Z"cf9d3a71f3d49395bfb37680aa37294c"129165STANDARDattachment/DPWG_CYP2D6_fluvoxamine_5993-5994-5995.pdf2024-03-08T02:34:54.000Z"e9535b554e982df82d85df6878192b9e"164972STANDARDattachment/DPWG_CYP2D6_gefitinib_4871-4872-4873.pdf2024-03-08T02:32:27.000Z"fc21b60451eda187c5bb86b406029d03"115266STANDARDattachment/DPWG_CYP2D6_haloperidol_1551-1552-1553.pdf2024-03-08T00:59:25.000Z"a11f13331a634cb89098dfafee8989be"394683STANDARDattachment/DPWG_CYP2D6_imipramine_1544-1545-1546.pdf2024-03-08T00:57:00.000Z"5c1c51fe4c346ef34c331f5fd1bbf4fb"201478STANDARDattachment/DPWG_CYP2D6_imipramine_2391-2393_downloaded_111125.pdf2025-11-11T22:17:20.000Z"e44636c02b6c283bfc596169a3d00a60"CRC64NVMEFULL_OBJECT244768STANDARDattachment/DPWG_CYP2D6_methylphenidate_2527-2528-2529.pdf2024-03-08T01:57:25.000Z"0b8d55f4d5279307dbe1661cfc053751"136919STANDARDattachment/DPWG_CYP2D6_metoprolol_1554-1555-1556.pdf2024-03-08T01:00:28.000Z"1eeba082e85b060a973b7d331a96a69b"353827STANDARDattachment/DPWG_CYP2D6_mirtazapine_2001-2002-2003.pdf2024-03-08T01:40:19.000Z"6c0da9d2ae293b94f38ced7bea11b29b"259269STANDARDattachment/DPWG_CYP2D6_nortriptyline_1557-1558-1559.pdf2024-03-08T01:01:46.000Z"780685593a09057a63af5cd84d39fdc1"211412STANDARDattachment/DPWG_CYP2D6_nortriptyline_2403-2405_downloaded_111125.pdf2025-11-11T22:30:07.000Z"cb89a931b613f59400f619d56e829d83"CRC64NVMEFULL_OBJECT359773STANDARDattachment/DPWG_CYP2D6_olanzapine_1560-1561-1562.pdf2024-03-08T01:02:57.000Z"d16c0edfd3252d0bd098f0b82ea92d17"256187STANDARDattachment/DPWG_CYP2D6_oxycodone_1586-1587-1588.pdf2024-03-08T01:06:15.000Z"e47dbc286b4837041852241e99b6fb9f"152493STANDARDattachment/DPWG_CYP2D6_paroxetine_1563-1564-1565.pdf2024-03-08T01:03:59.000Z"3e94ed95eb65b1a99306b8835acce838"228083STANDARDattachment/DPWG_CYP2D6_pimozide_2447-2448-2449.pdf2024-03-08T01:47:13.000Z"c17735e98d9dc20c13fb7a1f42420f25"248334STANDARDattachment/DPWG_CYP2D6_propafenone_1595-1596-1597.pdf2024-03-08T01:09:24.000Z"82f021e8052818f1a58d80d5b5f2d0dc"239899STANDARDattachment/DPWG_CYP2D6_quetiapine_2393-2394-2395.pdf2024-03-08T01:46:17.000Z"3ec028af8985216fe8f6dadbf338062f"211561STANDARDattachment/DPWG_CYP2D6_quinidine_2533-2534-2535.pdf2024-03-08T01:59:25.000Z"0d771646bf61c25b874dcb269ab4d253"117851STANDARDattachment/DPWG_CYP2D6_risperidone_1535-1536-1537.pdf2024-03-08T00:50:59.000Z"31aa50b2c57d45debde66a9ec655b612"534872STANDARDattachment/DPWG_CYP2D6_sertraline_3512-to-3514.pdf2024-03-08T02:12:46.000Z"9b357cd1b5655ef3b100e63552cc0087"116682STANDARDattachment/DPWG_CYP2D6_sotalol_2539-2540-2541.pdf2024-03-08T02:01:23.000Z"023b4008ee69d47d11af950c15351bc8"117053STANDARDattachment/DPWG_CYP2D6_tamoxifen_1601-1602-1603.pdf2024-03-08T01:11:37.000Z"c9b2e67bdbedec035023f737a78405e9"796416STANDARDattachment/DPWG_CYP2D6_tramadol_1589-1590-1591.pdf2024-03-08T01:07:21.000Z"3b0adf40fe783edc54b42e1e7ededeed"240538STANDARDattachment/DPWG_CYP2D6_venlafaxine_1538-1539-1540.pdf2024-03-08T00:54:08.000Z"29997442812badcd9f78af52e6be3a03"386491STANDARDattachment/DPWG_CYP2D6_zuclopenthixol_1547-1548-1549.pdf2024-03-08T00:58:19.000Z"e8c720ea6b17bddad1a92bfdbc53a9c4"267195STANDARDattachment/DPWG_CYP3A4_paclitaxel_7107-7113.pdf2024-03-08T02:49:31.000Z"ffe7780b71075fbc53635f9dcc5871d1"160661STANDARDattachment/DPWG_CYP3A4_quetiapine_5991-5992.pdf2024-03-08T02:34:05.000Z"8c40a065df892e04c9fd9289fc5dbeda"225746STANDARDattachment/DPWG_CYP3A5_tacrolimus_2357-2358.pdf2024-03-08T01:45:27.000Z"3a94a2ac162a5746642912702e80e93e"602500STANDARDattachment/DPWG_DPD_5-fluorouracil_capecitabine_2551-2552-4893-4894-6192.pdf2024-03-08T02:08:52.000Z"d2fa23e084e8dfa479f0c1f43b054ef0"577715STANDARDattachment/DPWG_DPD_flucytosine_7208-7209-7210-7211.pdf2024-03-08T02:52:03.000Z"a27554d392bdc5232545ba5461f48eb9"221392STANDARDattachment/DPWG_DPD_tegafur_with_DPD_inhibitor_2553-2554-4891-4892.pdf2024-03-08T02:10:04.000Z"f8b80be6f5e4c6c752bcf25a08b45e0b"170670STANDARDattachment/DPWG_February_2020.pdf2020-02-10T15:15:15.000Z"652341f413817a85cea11bd3411501d5"925849STANDARDattachment/DPWG_February_2022_guidelines.pdf2022-03-18T16:59:53.000Z"1170dfb77ddc7de91c83371d4f74b572"1004217STANDARDattachment/DPWG_HLA_abacavir_2356.pdf2024-03-08T01:44:37.000Z"00d998dde3193ccb60158223f82737be"527349STANDARDattachment/DPWG_HLA_allopurinol_6391.pdf2024-03-08T02:40:47.000Z"2c5405ff924beaf4ad5d1c8e88c65fe9"705988STANDARDattachment/DPWG_HLA_allopurinol_6391_03072024.pdf2025-05-16T19:11:09.000Z"2c5405ff924beaf4ad5d1c8e88c65fe9"CRC64NVMEFULL_OBJECT705988STANDARDattachment/DPWG_HLA_carbamazepine_6237-6238-6239.pdf2024-03-08T02:39:38.000Z"6f2757eabd72130528d040a2b0a7cf6d"781180STANDARDattachment/DPWG_HLA_flucloxacillin_4652.pdf2024-03-08T02:29:30.000Z"c646b5c32ce4c44cf6ce9890d8a7b6dc"224227STANDARDattachment/DPWG_HLA_lamotrigine_6932.pdf2024-03-08T02:43:50.000Z"9029cb018a5fcae3c8f58cee7833d309"436601STANDARDattachment/DPWG_HLA_oxcarbazepine_6931.pdf2024-03-08T02:43:02.000Z"bec38ca4e4d067efd2027e8dcc2c1ce3"406766STANDARDattachment/DPWG_HLA_phenytoin_6927.pdf2024-03-08T02:42:18.000Z"2a35421361b3ed315c0c7cff4a988f51"611106STANDARDattachment/DPWG_HLA_ribavirin_2343.pdf2024-03-08T01:42:54.000Z"2fd1127c49859453c9390da3d4440afb"308714STANDARDattachment/DPWG_MTHFR_folic_acid_7204-7205.pdf2024-03-08T02:51:11.000Z"17878df1cfdd76f9310643af27116447"408840STANDARDattachment/DPWG_MTHFR_methotrexate_5599-5600.pdf2024-03-08T02:33:16.000Z"7e8791b2bbeced52a0ddf5cdab998b87"612739STANDARDattachment/DPWG_May_2020.pdf2020-06-01T18:45:39.000Z"bc151ace27ee6bb41c173a28773110ee"5228052STANDARDattachment/DPWG_May_2021.pdf2022-02-24T19:23:12.000Z"36af8c1e5c00a669ec5902d90ad2e0fa"988971STANDARDattachment/DPWG_NUDT15-tioguanine_7033-7034.pdf2025-09-09T00:24:52.000Z"cd858923915bdcd8b102c79a06b6c419"CRC64NVMEFULL_OBJECT236271STANDARDattachment/DPWG_NUDT15_azathioprine_6-mercaptopurine_090825.pdf2025-09-08T21:13:58.000Z"37a66a189838daae983400f445b695f3"CRC64NVMEFULL_OBJECT765224STANDARDattachment/DPWG_NUDT15_azathioprine_6-mercaptopurine_7035-7036.pdf2024-03-08T02:47:48.000Z"e158c992f3cae28849f97f0ab80bad3d"733965STANDARDattachment/DPWG_NUDT15_thioguanine_7033-7034.pdf2024-03-08T02:47:00.000Z"d218c59ca68d69a74e943c6346b350ae"316043STANDARDattachment/DPWG_November_2018.pdf2019-10-02T23:46:14.000Z"111113609d13e446b7bf94a897a4e973"877353STANDARDattachment/DPWG_SLCO1B1_atorvastatin_4057-4058.pdf2024-03-08T02:25:19.000Z"17e9202e118b8e874e96db322b1579f0"351976STANDARDattachment/DPWG_SLCO1B1_fluvastatin_4059-4060.pdf2024-03-08T02:26:08.000Z"b9ead5f0fefd7e4404571771e3b5ca30"247850STANDARDattachment/DPWG_SLCO1B1_pravastatin_7742-7743.pdf2024-03-08T02:56:00.000Z"e115646539b92a5e136ae2033ac38910"220327STANDARDattachment/DPWG_SLCO1B1_rosuvastatin_7740-7741.pdf2024-03-08T02:55:11.000Z"d226ec0fea945bd7603e897e1e65f0ed"260648STANDARDattachment/DPWG_SLCO1B1_simvastatin_4055-4056.pdf2024-03-08T02:24:33.000Z"feb73f4eb7f0be080768849f011e4fad"383676STANDARDattachment/DPWG_TPMT_azathioprine_6-mercaptopurine_090825.pdf2025-09-08T20:32:27.000Z"a8e18b1c460356631750c16d11288cd5"CRC64NVMEFULL_OBJECT468910STANDARDattachment/DPWG_TPMT_azathioprine_6-mercaptopurine_1905-1906.pdf2024-03-08T01:32:08.000Z"b09889a7ee4188a854489d2018d147d5"715884STANDARDattachment/DPWG_TPMT_thioguanine_1907-1908.pdf2024-03-08T01:33:00.000Z"15e3c3ded8e0fb0f8e91ce5f329e637d"271968STANDARDattachment/DPWG_UGT1A1_atazanavir_06272025.pdf2025-06-27T21:54:58.000Z"f7bd01f68b1dc16a8700fe8c16d42fdd"CRC64NVMEFULL_OBJECT239000STANDARDattachment/DPWG_UGT1A1_atazanavir_7736-to-7739.pdf2024-03-08T02:54:15.000Z"487ebdbf1a73e16bd99026e54ae38a20"323669STANDARDattachment/DPWG_UGT1A1_irinotecan_1691-to-1694.pdf2024-03-08T01:16:05.000Z"e415f1f8b19bf9491c84e72dd0882f96"734941STANDARDattachment/DPWG_VKORC1_acenocoumarol_1909-1910.pdf2024-03-08T01:34:02.000Z"17afbac7b2038e12747e13f2b69a23b2"535487STANDARDattachment/DPWG_VKORC1_phenprocoumon_1911-1912.pdf2024-03-08T01:35:17.000Z"d6b490e7decb46b7c756462f3991d79d"527327STANDARDattachment/DPWG_VKORC1_warfarin_6235-6236.pdf2024-03-08T02:38:43.000Z"42f8a79428f4ce9bd82b7027700a4589"297156STANDARDattachment/DPWG_Warfarin_doses_day_4_and_5_calculation_for_different_genotypes.xlsx2024-03-20T13:02:18.000Z"cbecc0705926b0dd7391c69344223b95"17650STANDARDattachment/DPWG_Warfarin_loading_doses_calculation_for_different_genotypes.xlsx2024-03-19T19:13:52.000Z"0232b002391bfe466311ed9eb0064112"16903STANDARDattachment/DPYD.pdf2022-09-16T16:05:53.000Z"2d2efd1038a2f0022344d2ae48c6f367"312942STANDARDattachment/DPYD_Allele_Frequency_Table.xlsx2020-04-15T21:13:30.000Z"733b77ec243427870313a57ad370c5e5"167438STANDARDattachment/DPYD_Allele_Functionality_Table.xlsx2020-04-15T21:18:16.000Z"ef18e566da75a94d2646e9c1d2ad7ecb"17744STANDARDattachment/DPYD_CPIC_Supp_final.pdf2016-11-16T19:45:08.000Z"3315f8e5f4a1bb1e15d67850a8bbe4f6"160382STANDARDattachment/DPYD_Diplotype_Phenotype_Table.xlsx2020-04-15T21:21:40.000Z"a38a0dfabd988a50c859b52aea44d70c"57153STANDARDattachment/DPYD_Gene_Resource_Mappings.xlsx2018-03-23T00:02:18.000Z"8fd9c56cb15b8a6691caf0e7fdbd71be"35461STANDARDattachment/DPYD_VIP_Summary.pdf2024-10-19T06:16:58.000Z"fa934bf9a09f6f6448c26ac86ad9310a"55459STANDARDattachment/DPYD_allele_definition_table.xlsx2024-07-09T22:56:41.000Z"6ebeb4b152d2a6848010b9993b3bf465"13217STANDARDattachment/DPYD_allele_functionality_table_reference.xlsx2020-04-15T21:16:39.000Z"ef18e566da75a94d2646e9c1d2ad7ecb"17744STANDARDattachment/DPYD_online_manuscript.pdf2016-11-16T19:45:07.000Z"4c43ac216d666d534129c63950015819"578009STANDARDattachment/DPYD_supplemental_variant_table.xlsx2020-04-15T21:09:15.000Z"e1ea348f32b92b6117916b55aab418b6"16725STANDARDattachment/DPYD_uncertain_function_variants.xlsx2020-02-24T20:38:09.000Z"8b468d8c390134df83f44fe4ec054cf8"16012STANDARDattachment/Dabrafenib_01_10_19_FDA.pdf2019-03-05T22:31:52.000Z"e8390526075b9f23bceed5d2b2eb9506"2296573STANDARDattachment/Dabrafenib_03_02_16_FDA.pdf2016-11-16T19:47:00.000Z"03ce0b3ee4f1582f09ab6ea232514aad"974614STANDARDattachment/Dabrafenib_03_15_17_FDA.pdf2017-03-15T20:18:03.000Z"78bad8114edf70eae9ee99f6e129af8b"598199STANDARDattachment/Dabrafenib_06_20_19_EMA.pdf2019-06-20T18:58:11.000Z"ce66d2281ad93845d0ae99851d99a123"1928092STANDARDattachment/Dabrafenib_12_16_2013_FDA.pdf2016-11-16T19:45:50.000Z"1442aa5d42184e8431da2fa55d1295b6"355004STANDARDattachment/Dabrafenib_2024_05_14_EMA.pdf2024-05-14T22:29:52.000Z"a064e89514bda1ae319c49e562fae192"672848STANDARDattachment/Dabrafenib_2024_05_14_HCSC.pdf2024-05-14T23:08:48.000Z"0f57969e4eaaba3e179e94264c2b6054"1924450STANDARDattachment/Dabrafenib_2025_01_17_FDA.pdf2025-01-17T23:14:46.000Z"6a109702783abe8889624a88338be2bb"2189854STANDARDattachment/Dabrafenib_FDA_2023_11_30.pdf2023-11-30T15:18:10.000Z"4b1ec7ac408a20c4e0a89a053f8e0d3d"1812619STANDARDattachment/Dabrafenib_FDA_label_20220829.pdf2022-08-30T00:50:12.000Z"ad62c580ce44ce6b161134c1a547334f"971675STANDARDattachment/Dabrafenib_HCSC_05_21_15.pdf2016-11-16T19:47:21.000Z"6ce52029aa1b41934213ba3721163bee"896257STANDARDattachment/Daclatasvir_03_17_17_FDA.pdf2017-03-17T21:19:35.000Z"08bbb28b9ab6dc9fccdd64a45ee122df"580076STANDARDattachment/Daclatasvir_07_17_2017_FDA.pdf2019-03-04T20:17:26.000Z"a5d68b8553ef9a3ecca3c42dbb1c924e"714819STANDARDattachment/Dacomitinib_03_29_19_FDA.pdf2019-03-29T22:48:25.000Z"f81aa2a163eacbeeeaf20b5fd6e14fcf"1254056STANDARDattachment/Dacomitinib_06_20_19_EMA.pdf2019-06-20T21:08:07.000Z"8d0bcdae0c719be268996e700d9eeb77"1061156STANDARDattachment/Dacomitinib_2025_07_09_HCSC.pdf2025-07-09T22:27:20.000Z"2b063f1032f2ed11cc9dafa7f5af68a4"CRC64NVMEFULL_OBJECT967924STANDARDattachment/Dactinomycin_08_27_21_FDA.pdf2021-08-27T22:35:59.000Z"0136484730ef2ec317861bdd07bd2a6f"658606STANDARDattachment/Dapsone_01_10_19_FDA.pdf2019-03-04T20:18:00.000Z"69b452d376015fac43460c679c6a00c3"1046972STANDARDattachment/Dapsone_2024_07_19_HCSC.pdf2024-07-19T23:09:58.000Z"afaa2dd49f3989c0487184476404c84a"416303STANDARDattachment/Dapsone_2024_11_26_FDA.pdf2024-11-26T22:01:26.000Z"af708684eff0a171be5df51354d30a78"2178113STANDARDattachment/Dapsone_2024_11_26_HCSC.pdf2024-11-26T22:33:35.000Z"2e5e383ea6573eaca05552bd8103a88c"117911STANDARDattachment/Dapsone_FDA_label_Oct_18_2013.pdf2016-11-16T19:45:28.000Z"166ad0e08617b4f19313cd9b9462a0bd"191329STANDARDattachment/Dapsone_Gel_06_28_11.pdf2016-11-16T19:44:33.000Z"b1f2781d7988b46baca7250a1831033e"546871STANDARDattachment/Dapsone_HCSC_05_21_15.pdf2016-11-16T19:47:21.000Z"970de22d9c88bf0934f5cc9df65ce2db"389752STANDARDattachment/Dapsone_PMDA_10_04_16.pdf2016-11-16T19:47:02.000Z"2b853649a8d9b5fad0bd5930f6df5d2c"245865STANDARDattachment/Dapsone_Tablet_06_28_11.pdf2016-11-16T19:44:33.000Z"df5a69c95b677aefbf9c536671cdf7f7"263364STANDARDattachment/Darifenacin_06_20_19_EMA.pdf2019-06-20T21:14:24.000Z"782cf9ac4a4eeaca98ee9df4770be169"633899STANDARDattachment/Darifenacin_07_17_2017_FDA.pdf2019-03-04T20:18:32.000Z"d5ff22c2b4f761f16016fe3b81ec4031"862042STANDARDattachment/Darifenacin_2024_07_19_FDA.pdf2024-07-19T23:47:01.000Z"3945fbfb512eaddad70c353fa7d84c2a"451188STANDARDattachment/Darifenacin_2024_12_02_HCSC.pdf2024-12-02T19:50:48.000Z"e828f79aaea707e2cc56858dc00a129a"763138STANDARDattachment/Darifenacin_FDA_Label_8_8_2014.pdf2016-11-16T19:46:13.000Z"656ca422f08fb85b5613b2670f0e36d7"538946STANDARDattachment/Darifenacin_HCSC_05_22_15.pdf2016-11-16T19:47:09.000Z"e718e3094c06029b7013df57dbd4c531"329663STANDARDattachment/Dasabuvir_Ombitasvir_Paritaprevir_Ritonavir_1_11_19_FDA.pdf2019-03-04T20:19:13.000Z"f0d5f1381c2f2f6ca5043160c2ef3458"5784699STANDARDattachment/Dasatinib_01_11_19_FDA.pdf2019-03-04T20:20:14.000Z"6af4e37d47ac62971eb2040ae39f0505"948545STANDARDattachment/Dasatinib_06_20_19_EMA.pdf2019-06-20T21:23:14.000Z"d931feb6608cc492ae075e6131125a67"1746170STANDARDattachment/Dasatinib_10_17_13.pdf2016-11-16T19:45:45.000Z"f229afce238fa21801c3593f5b75e759"495020STANDARDattachment/Dasatinib_2024_08_06_HCSC.pdf2024-08-06T16:30:28.000Z"a37d9608fd1d080db5886caf6f3cad66"1550599STANDARDattachment/Dasatinib_HCSC_05_22_15.pdf2016-11-16T19:46:27.000Z"380a6b06bd4a17fb21cd60c57b29f482"887866STANDARDattachment/Dasatinib_PMDA_11_17_14.pdf2016-11-16T19:46:38.000Z"2f32ca8b2e826ca67d2686b95dbaec92"555291STANDARDattachment/Daunorubicin_10_07_21_FDA.pdf2021-10-08T18:21:17.000Z"33ab6b7d667036e6383364b33b8675b3"280376STANDARDattachment/Decision_tree_for_irinotecan_dosing.png2016-11-16T19:46:57.000Z"ba8db0a4ca5013c8bac84a6073c47042"203018STANDARDattachment/Deferasirox_12_8_21.pdf2021-12-08T18:06:15.000Z"392e8a3171c5c83308a793a71a537fe7"332727STANDARDattachment/Denileukin_Diftitox_07_07_2017_FDA.pdf2019-03-04T20:20:49.000Z"11591d64790bf8fd7ec2f71c07007248"395781STANDARDattachment/Denileukin_Diftitox_5_9_2012.pdf2016-11-16T19:44:59.000Z"7464f296c1c0bbdf42302bd33e13efaa"309688STANDARDattachment/Denileukin_diftitox_2024_08_06_FDA.pdf2024-08-06T17:55:43.000Z"ad3eb3da6a06bf0aa08492953946df6b"436416STANDARDattachment/Desflurane_01_11_19_FDA.pdf2019-03-04T20:21:22.000Z"64c8a023a55a3d4dfdd99c85a71c473a"1677083STANDARDattachment/Desflurane_20230330_FDA.pdf2023-03-31T20:56:09.000Z"8acbf8b760ae0c5a5d1b6e7879515ddc"564343STANDARDattachment/Desflurane_2024_09_19_HCSC.pdf2024-09-19T18:56:53.000Z"4c9aabdd7cf4712463dea57bc9d54103"704017STANDARDattachment/Desipramine_01_11_19_FDA.pdf2019-03-04T20:22:00.000Z"1ccd4402d4e94b75668ded592645caf5"791716STANDARDattachment/Desipramine_10_15_13.pdf2016-11-16T19:45:05.000Z"38d0979fe2c38eb1894d16ef053bcf85"417810STANDARDattachment/Desipramine_2024_11_05_HCSC.pdf2024-11-05T19:21:05.000Z"31281ff9bd657a48c3d41170c80275c7"732034STANDARDattachment/Desloratadine_and_Pseudoephedrine_3_16_12.pdf2016-11-16T19:45:34.000Z"92280077abdb4b2a7b0a86e72c333e7f"291420STANDARDattachment/Desmopressin_FDA_2023_03_15.pdf2023-03-16T13:19:36.000Z"fefa850512bd1cd2dbcf976c7fdb7407"826026STANDARDattachment/Desmopressin_HCSC_2023_03_21.pdf2023-03-21T15:41:09.000Z"05599b031f7c4a17fe27c980faa49792"136133STANDARDattachment/Desvenlafaxine_2024_11_05_HCSC.pdf2024-11-05T19:43:01.000Z"5a2ac8183ea936f83c5e83fe0669e9dd"792237STANDARDattachment/Desvenlafaxine_FDA_02_12_18.pdf2018-02-15T22:20:47.000Z"efac7a3c6eb19970309a72e0d0f2fb48"1677131STANDARDattachment/Deuruxolitinib_2025_05_07_FDA.pdf2025-05-08T16:55:35.000Z"962e1fbeb5beaf79a8ee98c3c1af1ac9"CRC64NVMEFULL_OBJECT2028662STANDARDattachment/Deutetrabenazine_08_29_17_FDA.pdf2019-03-04T20:22:42.000Z"9b4651bc585f64c9dae41133f2887b9d"803086STANDARDattachment/Dexamethasone_FDA_09012021.pdf2021-09-01T17:17:08.000Z"062417a693aaede7bcdb6c502d6f9c0a"127017STANDARDattachment/Dexlansoprazole_01_11_19_FDA.pdf2019-03-04T20:23:07.000Z"9e7b89a397d11c935dd876ad113d05c5"1252912STANDARDattachment/Dexlansoprazole_10_17_13.pdf2016-11-16T19:44:27.000Z"ef820444b275e6ec2e13405bd719c1ec"461579STANDARDattachment/Dexlansoprazole_2024_12_02_HCSC.pdf2024-12-02T21:17:57.000Z"f093148d3229ce538aff22782bbe456f"736756STANDARDattachment/Dexlansoprazole_3_19_12.pdf2016-11-16T19:45:34.000Z"780bd643048836c0d6c2e96fc7647cdf"222762STANDARDattachment/Dexlansoprazole_HCSC_05_22_15.pdf2016-11-16T19:46:40.000Z"d0e1883a2642d45ce5db951b2f129b95"541832STANDARDattachment/Dexmedetomidine_4_29_2022.pdf2022-04-29T19:39:15.000Z"e4de638c301a71a38b0302a73a936290"392014STANDARDattachment/Dextroamphetamine_12_1_2021.pdf2021-12-01T16:51:36.000Z"2ff71db65231c7ca7b96b5d8a54676f8"69235STANDARDattachment/Dextromethorphan_and_Quinidine_07_17_2017_FDA.pdf2019-03-04T20:23:42.000Z"4feb0c8fe4526f6418b0557c51655080"652197STANDARDattachment/Dextromethorphan_and_Quinidine_5_9_2012.pdf2016-11-16T19:44:23.000Z"f8b426270483d53e69c4542a1e7de1ca"615244STANDARDattachment/Dextromethorphan_hydrobromide_and_bupropion_hydrochloride_2024_10_02_FDA.pdf2024-10-03T00:52:42.000Z"6d942e7a0ad273a895d6effa81ba0543"994322STANDARDattachment/Dextromethorphan_quinidine_EMA_EPAR_May_02_2014.pdf2016-11-16T19:46:14.000Z"070cc59037ad40957c618bc1cc123a96"325039STANDARDattachment/Diazepam_01_11_19_FDA.pdf2019-03-04T20:24:14.000Z"ba4110a7cbaab71a351bbeb6bede98fd"1344192STANDARDattachment/Diazepam_10_16_2013.pdf2016-11-16T19:45:11.000Z"75b41e5b024ba3d04108f4864947312c"575947STANDARDattachment/Diazepam_2024_11_05_HCSC.pdf2024-11-05T21:13:14.000Z"3883112237f0a894773ff664ebc5f7aa"866960STANDARDattachment/Diazepam_7_26_2011.pdf2016-11-16T19:44:33.000Z"ec69349665ade68b1e6ff0fd7acc642b"234804STANDARDattachment/Diazepam_Valium_2024_11_05_HCSC.pdf2024-11-05T21:13:24.000Z"6b71c628c06360d16a642594eeb57144"504097STANDARDattachment/Dimercaprol_12_1_2021.pdf2021-12-01T16:15:08.000Z"61ee882336df4ce2cfb8dd36d41d59d4"34031STANDARDattachment/Dinutuximab_07_17_2017_FDA.pdf2019-03-04T20:25:51.000Z"ff851551e7120561dde027c7ddce4ea9"459674STANDARDattachment/Dinutuximab_FDA_08_18_16.pdf2016-11-16T19:47:42.000Z"d1168dd3c1041b4f41571361184f7992"461868STANDARDattachment/Divalproex_05_29_15_FDA.pdf2016-11-16T19:47:09.000Z"bab86502ce607e6c7c313cce4ab67e85"1083740STANDARDattachment/Divalproex_HCSC_06_01_15.pdf2016-11-16T19:46:56.000Z"83e92631bd4cd6d258137c6f80a7f9a1"675004STANDARDattachment/Divalproex_Sodium_01_11_19_FDA.pdf2019-03-04T20:26:29.000Z"b1d4d0059206420a8c038a9ff4b3d30d"1810337STANDARDattachment/Docetaxel_05_13_2019FDA.pdf2019-05-15T17:44:39.000Z"03b4ef3566b8f5aa200c8886f024c01d"2013856STANDARDattachment/Dolutegravir_01_14_19_FDA.pdf2019-03-04T20:27:10.000Z"4905a106ca7037c13be946b42be7e116"3551853STANDARDattachment/Dolutegravir_06_20_19_EMA.pdf2019-06-20T22:02:54.000Z"49f8976354380fcf9203db49e702ab64"463638STANDARDattachment/Dolutegravir_2024_07_19_HCSC.pdf2024-07-20T00:26:39.000Z"7b1a0b01fa1919fc458882166dc144e2"703707STANDARDattachment/Dolutegravir_FDA_08_17_16.pdf2016-11-16T19:47:13.000Z"b212c26da57c2448b7d1e56c3156e879"794426STANDARDattachment/Donanemab-azbt_2025_05_15_FDA.pdf2025-05-15T19:02:23.000Z"4f9e98ab64d69c92d228e624f2b43c85"CRC64NVMEFULL_OBJECT891281STANDARDattachment/Donanemab_2025_10_28_EMA.pdf2025-10-28T21:20:57.000Z"98de2831a7c2c3977e30ae846f1e37a9"CRC64NVMEFULL_OBJECT585226STANDARDattachment/Donepezil_01_15_19_FDA.pdf2019-03-04T20:27:46.000Z"559e2cae10df38cd1747eb0f832cc677"788799STANDARDattachment/Donepezil_2024_10_16_HCSC.pdf2024-10-16T21:54:41.000Z"0601c09eae1ca7917273dfe5359378c7"885752STANDARDattachment/Donepezil_FDA_03_08_17.pdf2017-03-08T17:33:02.000Z"7a3e1edb7ade0c5bbaf300bc72bdd498"563346STANDARDattachment/Dopamine_4_5_2022.pdf2022-04-05T20:27:10.000Z"2a1a0bafc10db79176c3a6fb8a4d48cc"695326STANDARDattachment/Dostarlimab_2024_06_18_HCSC.pdf2024-06-18T22:25:00.000Z"7a34da0ea21c6d408440d42a53e9c788"721079STANDARDattachment/Dostarlimab_2024_08_06_EMA.pdf2024-08-06T19:51:11.000Z"16124396a8e7872339f73409668f8bca"669797STANDARDattachment/Doxepin_10_1_24_AEMPS.pdf2024-10-01T19:48:59.000Z"21edc54fb46aa964af4fc67e6eea4f48"259063STANDARDattachment/Doxepin_2024_11_05_HCSC.pdf2024-11-05T21:59:34.000Z"72e0a6d33ce3b47def356f470011dbe7"262026STANDARDattachment/Doxepin_9_7_11.pdf2016-11-16T19:44:34.000Z"562bff719f01fe6314783224da20fa7b"307770STANDARDattachment/Doxepin_Silenor_07_17_2017_FDA.pdf2019-03-04T20:28:20.000Z"b172aa43885df3ffc38f0b2c490ecf75"670148STANDARDattachment/Doxepin_Zonalon_01_15_19_FDA.pdf2019-03-04T20:28:26.000Z"612d6c17098d54eb1daaee73dba16582"860462STANDARDattachment/Doxorubicin_12_7_2022.pdf2022-12-07T20:56:49.000Z"dff7e163ff71dbe62dc971dfae5537c4"5017163STANDARDattachment/Doxycycline_4_27_2022.pdf2022-04-27T18:04:59.000Z"ad2263933f6c1fa9f2093b6961140dc1"714518STANDARDattachment/Dronabinol_03_17_17_FDA.pdf2017-03-17T21:28:30.000Z"45ed8cbcdee6ccec8f910a4508564faf"1128605STANDARDattachment/Dronabinol_08_04_2017_FDA.pdf2019-03-04T20:29:35.000Z"fd4ddb0abe5308161c457b1fcc1f066b"1140626STANDARDattachment/Dronabinol_2025_01_30_FDA.pdf2025-01-31T01:16:35.000Z"7a5e3b695a17488ff1d43de22b150b77"1089590STANDARDattachment/Dronedarone_2025_08_01_EMA.pdf2025-08-01T17:33:08.000Z"1221d7643e4f10d5fed8b2a3c6269015"CRC64NVMEFULL_OBJECT431006STANDARDattachment/Drospirenone_Ethinyl_Estradiol_01_15_19_FDA.pdf2019-03-04T21:16:59.000Z"e5bcfad3b93036cc8b665cfa254219ec"1379158STANDARDattachment/Drospirenone_and_ethinyl_estradiol_10_16_13.pdf2016-11-16T19:45:11.000Z"09df959939ca7dfea39a77f6e1bfd6a6"792797STANDARDattachment/Drospirenone_and_ethinyl_estradiol_6_28_2011.pdf2016-11-16T19:44:34.000Z"688724b6b48324d5318f77582ec22eb3"974593STANDARDattachment/Drospirenone_and_ethinyl_estradiol_HCSC_03_02_2017.PDF2024-07-18T19:22:40.000Z"318bbf44505aaf5bad510a797893af07"1446432STANDARDattachment/Drospirenone_and_ethinyl_estradiol_HCSC_06_01_15.pdf2016-11-16T19:47:09.000Z"30f56507a81f0cce9a2f90c21283661d"878015STANDARDattachment/Drospirenone_ethinylestradiol_2025_08_01_FDA.pdf2025-08-01T18:10:39.000Z"d495931af9c1439a54b60320a1041f6d"CRC64NVMEFULL_OBJECT1782847STANDARDattachment/Duloxetine_03_17_17_FDA.pdf2017-03-17T21:10:47.000Z"719ac6e37ce8f686fc11af20aebeccfa"1098983STANDARDattachment/Duloxetine_06_20_19_EMA.pdf2019-06-20T22:14:44.000Z"8073a023089808692f9ebccdc4352dc5"357215STANDARDattachment/Duloxetine_07_19_2017_FDA.pdf2019-03-04T21:19:36.000Z"8f44eab1b6aa27f52f03858252da060e"1141484STANDARDattachment/Duloxetine_2024_10_17_HCSC.pdf2024-10-18T00:50:57.000Z"14f941507e3d23e033b8fbc04b29c608"733490STANDARDattachment/Duloxetine_2025_08_01_FDA.pdf2025-08-01T18:40:39.000Z"e87ddec90dafa63414c79369ade95250"CRC64NVMEFULL_OBJECT1352291STANDARDattachment/Duloxetine_2025_08_01_HCSC.pdf2025-08-01T18:51:59.000Z"3402a95e21f0befa38eb2061287478a3"CRC64NVMEFULL_OBJECT874316STANDARDattachment/Duloxetine_FDA.pdf2017-03-17T21:10:21.000Z"719ac6e37ce8f686fc11af20aebeccfa"1098983STANDARDattachment/Durvalumab_01_15_19_FDA.pdf2019-03-04T21:20:16.000Z"239bf19aff40af2490b45ca39a4c1e4c"1056227STANDARDattachment/Durvalumab_08_29_17_FDA.pdf2017-08-29T22:39:21.000Z"b9273a99778db930b006aa3c883d9fc1"320830STANDARDattachment/Durvalumab_2024_10_03_EMA.pdf2024-10-03T23:06:40.000Z"5ec5a20be6d7ac49436cd05d3f4eb47d"1880580STANDARDattachment/Durvalumab_2024_10_03_FDA.pdf2024-10-03T21:54:09.000Z"0e0c02be5662a5998ac1d251e297ea74"24706527STANDARDattachment/Durvalumab_EMA_2023_03_21.pdf2023-03-21T17:25:05.000Z"be3bae279283d0cbbff69bc076bd6863"1104638STANDARDattachment/Durvalumab_FDA_2023_03_15.pdf2023-03-16T15:04:54.000Z"8cfcbd15a0811f040a922159e06fcc5c"1499282STANDARDattachment/Durvalumab_HCSC_2023_03_21.pdf2023-03-21T17:53:25.000Z"ec7bc2f52836a1a8c55c5e18ddc0e010"1338062STANDARDattachment/Duvelisib_05_13_2019FDA.pdf2019-05-15T17:45:16.000Z"10daaef3a053439eb4e0a44cfc51b322"344122STANDARDattachment/EPCLUSA_03_17_17_FDA.pdf2017-03-17T18:40:22.000Z"f91c2ee799b252d6bc264bb5869f5c04"506294STANDARDattachment/ERBB2_VIP_Summary.pdf2024-10-19T06:17:06.000Z"68d8c01a892289fae13feb7f4c05a5aa"33061STANDARDattachment/ES259564.png2026-01-14T14:04:03.000Z"f6ab40abf88e48c5ab0bc89a87c599c0"CRC64NVMEFULL_OBJECT47100STANDARDattachment/EVINACUMAB-DGNB_FDA_20230906.pdf2023-09-08T00:29:51.000Z"8a2b3c81779e0aa3e11f0090ec1a9c7a"787885STANDARDattachment/Efavirenz_03_17_17_FDA.pdf2017-03-17T20:39:45.000Z"9f52b02f341dedb84f59338e9bb44d87"1321879STANDARDattachment/Efavirenz_06_20_19_EMA.pdf2019-06-20T22:25:23.000Z"1f280459c4a180fd54b5535df8564cb9"1038541STANDARDattachment/Efavirenz_07_19_17_FDA.pdf2019-03-04T21:22:27.000Z"32fc60dc24c9fa57f88cc85bb1cd54b7"1435290STANDARDattachment/Efavirenz_07_19_24_FDA.pdf2024-07-19T01:00:09.000Z"d390038660b9f9e516ec24bd313dd5e9"2512889STANDARDattachment/Efavirenz_10_1_24_AEMPS.pdf2024-10-01T19:52:24.000Z"e32c33a9edecbed0ed0d8ff4bdf5a77c"652767STANDARDattachment/Efavirenz_2024_11_05_HCSC.pdf2024-11-05T22:22:42.000Z"46319d6f121ca43f405a7879c4a98f46"999828STANDARDattachment/Efavirenz_Emtricitabine_Tenofovir_06_20_19_EMA.pdf2019-06-20T22:39:40.000Z"e38423b61c57fabc11c326d9513c4c63"993091STANDARDattachment/Efavirenz_PMDA_08_18_16.pdf2016-11-16T19:46:45.000Z"ca50b7f74740513e5e4f4de15f54a8cb"505683STANDARDattachment/Efavirenz_emtricitabine_tenofovir_2024_12_02_HCSC.pdf2024-12-02T21:47:42.000Z"c376003c8c2e8eee45d3389bd3e262d5"1405837STANDARDattachment/Efavirenz_emtricitabine_tenofovir_HCSC_06_01_15.pdf2016-11-16T19:46:40.000Z"4fc7a5a336d173bff0cb9ddd3222b6bb"1130141STANDARDattachment/Efavirenz_emtricitabine_tenofovirdisoproxil_2025_08_04_FDA.pdf2025-08-04T20:42:33.000Z"f6dedf39c2daf7a8656927e687c222bf"CRC64NVMEFULL_OBJECT673125STANDARDattachment/Efgartigimod_04_04_22_FDA.pdf2022-04-04T21:53:38.000Z"b199e620c347d7952f4f153686fe444c"287778STANDARDattachment/Efgartigimod_alfa_2024_05_09_HCSC.pdf2024-05-09T19:03:57.000Z"4931f892b902d20948ae0298d119d8b8"495202STANDARDattachment/Eflornithine_EMA_2024_03_05.pdf2024-03-05T15:22:55.000Z"300ea13e82a2870fb9ce74b7f8a59662"342607STANDARDattachment/Eflornithine_FDA_2024_03_05.pdf2024-03-05T15:09:25.000Z"8991058552a519cb72829116ca35bae2"807802STANDARDattachment/Eflornithine_HCSC_2024_03_05.pdf2024-03-05T15:45:18.000Z"4351f30605efbe64dc0c244408a789c7"550748STANDARDattachment/Elacestrant_2024_05_22_EMA.pdf2024-05-22T21:32:14.000Z"967d1b3890c823d8a0da024ced62c23a"338821STANDARDattachment/Elacestrant_FDA_2023_09_07.pdf2023-09-07T18:31:42.000Z"2a2aa5de95caad4f7a8dc102b44949e6"511823STANDARDattachment/Elagolix_05_13_2019FDA.pdf2019-05-15T17:46:47.000Z"9c56915efecc7ce4f3a5182b6ec2ea2b"1328168STANDARDattachment/Elagolix_06_05_2023_FDA.pdf2024-07-19T16:21:29.000Z"25c8469f7d15d48f8be9744cc395ea11"1481876STANDARDattachment/Elagolix_2024_11_05_HCSC.pdf2024-11-05T23:03:54.000Z"5b17b6b82132af44b42d223b609ba3af"818798STANDARDattachment/Elbasvir_and_Grazoprevir_03_21_17_FDA.pdf2019-03-04T21:22:58.000Z"88763ed4d594ff8e8e9dc3d31ee7b0c4"869938STANDARDattachment/Elexacaftor_Tezacaftor_Ivacaftor_10_1_24_AEMPS.pdf2025-09-02T21:07:43.000Z"ee0cc5dc6c40a690edf5c0d3b0bf141b"CRC64NVMEFULL_OBJECT1108974STANDARDattachment/Eliglustat_01_16_19_FDA.pdf2019-03-04T21:23:40.000Z"202a7381ff94dfb00ecc251c87a4146e"1935549STANDARDattachment/Eliglustat_06_21_19_EMA.pdf2019-06-21T17:03:17.000Z"7ed024092a942582194b27ee29ee45c0"1349538STANDARDattachment/Eliglustat_10_1_24_AEMPS.pdf2024-10-01T20:00:02.000Z"2c4b3b6273595adb3fcd5cad31dd55f6"652438STANDARDattachment/Eliglustat_2024_05_01_HCSC.pdf2024-05-02T01:22:48.000Z"9b1b90a72bc2c01becf07b9342f4a53c"636012STANDARDattachment/Eliglustat_2025_04_16_EMA.pdf2025-04-23T17:57:02.000Z"5740b615f7344f86d0514dc9e30c843b"CRC64NVMEFULL_OBJECT622565STANDARDattachment/Eliglustat_EMA_EPAR_09_17_15.pdf2016-11-16T19:46:27.000Z"1e2402a8c18c777a4d9ad014d80f9e34"388526STANDARDattachment/Eliglustat_FDA_Label_10_30_14.pdf2016-11-16T19:47:28.000Z"07f6a1ec0b212629d43b962886bb9353"416610STANDARDattachment/Eliglustat_PMDA_10_05_16.pdf2016-11-16T19:47:45.000Z"dc5dca70953e7a70cc7b1145dbbdd921"420486STANDARDattachment/Elosulfase_Alfa_06_13_16_FDA.pdf2016-11-16T19:47:40.000Z"b817a2eba7609c156b2ce4e306213824"598711STANDARDattachment/Elosulfase_Alfa_06_21_19_EMA.pdf2019-06-21T17:10:07.000Z"aba213ae0ec40078c0ca985e78b23a96"462987STANDARDattachment/Elosulfase_Alfa_07_20_2017_FDA.pdf2019-03-04T21:24:22.000Z"e26cce402467ca88848f9b6f8f96a276"594755STANDARDattachment/Elosulfase_alfa_2024_08_06_HCSC.pdf2024-08-06T20:42:51.000Z"0772889bffad336e426d13d3e43ca15e"810371STANDARDattachment/Elranatamab_EMA_2024_03_05.pdf2024-03-05T16:39:06.000Z"c87dc641492df80915ae4d761b315874"462229STANDARDattachment/Elranatamab_FDA_2024_03_05.pdf2024-03-05T16:11:10.000Z"e3395d3da7b2f4d7e80d8b6b6fc8693e"7910782STANDARDattachment/Elranatamab_HCSC_2024_03_05.pdf2024-03-05T16:21:46.000Z"d690717527c0ba6c680eec50543484a7"720666STANDARDattachment/Eltrombopag_01_16_19_FDA.pdf2019-03-04T21:24:56.000Z"d2a4040283e539fb5545fc7f269c7306"1517621STANDARDattachment/Eltrombopag_06_21_19_EMA.pdf2019-06-21T17:14:33.000Z"91a3f0f3c92e76c7659806dbbb043c67"1562832STANDARDattachment/Eltrombopag_10_15_2012.pdf2016-11-16T19:45:02.000Z"1ca2bae7cfea5ae405042507da03d60a"290155STANDARDattachment/Eltrombopag_10_17_13.pdf2016-11-16T19:45:26.000Z"1f232e62f7a9318e56e8f693dccb92de"354762STANDARDattachment/Eltrombopag_HCSC_06_01_15.pdf2016-11-16T19:46:28.000Z"666e6194702668a1c4634ac9b32fd5c3"802951STANDARDattachment/Eltrombopag_HCSC_11_03_21.pdf2024-07-19T16:54:15.000Z"83690b73e3259be74f05bf3c45f0859f"2023249STANDARDattachment/Eltrombopag_PMDA_10_05_16.pdf2016-11-16T19:46:36.000Z"94ff0b4217144c131f3fe3a24cb958cf"631911STANDARDattachment/Eltrombopag_PMDA_11_17_14.pdf2016-11-16T19:47:28.000Z"8db6c7286f86b8703fa4d6eeecb5f20a"753845STANDARDattachment/Emapalumab_05_13_2019FDA.pdf2019-05-15T17:47:25.000Z"ab54900023b18b22c638b9085e09070f"793609STANDARDattachment/Enasidenib_FDA_02_12_18.pdf2019-03-04T21:25:31.000Z"0890e7d7beedcdd69bfc13810ccaa61f"739837STANDARDattachment/Encorafenib_06_21_19_EMA.pdf2019-06-21T17:22:10.000Z"a810ab6c8b66369c46f4f42c9f1fa4f5"418360STANDARDattachment/Encorafenib_08_08_18_FDA.pdf2018-08-08T22:55:54.000Z"38fd98423f3a53b13933407dc3b309b9"1121908STANDARDattachment/Encorafenib_2024_08_14_HCSC.pdf2024-08-14T20:45:30.000Z"e1ff326f5802b4b883a09935906a7d35"864333STANDARDattachment/Encorafenib_EMA_2022_12_01.pdf2022-12-01T21:57:54.000Z"14098062305c4461980078ce9e1a920a"838940STANDARDattachment/Encorafenib_HCSC_2022_12_01.pdf2022-12-01T21:58:11.000Z"786ff485da5530a1944386ef635237e9"1485467STANDARDattachment/Enflurane_08_30_17_FDA.pdf2019-03-04T21:25:54.000Z"327c72dbaeea125702dc9f3d18ebcc24"161185STANDARDattachment/EnfortumabVedotin_EMA_2022_11_29.pdf2022-11-29T18:43:27.000Z"2d41e96ebcc0ac228f6fe6fe07e65612"454893STANDARDattachment/Ensartinib_2025_05_16_FDA.pdf2025-05-16T23:48:39.000Z"bf4541bc24358d8733c80d788966e56c"CRC64NVMEFULL_OBJECT892475STANDARDattachment/Entrectinib_EMA_2022_11_29.pdf2022-11-30T15:31:39.000Z"cc7f5a5c3dc573008bf08d71caf217a4"449756STANDARDattachment/Entrectinib_HCSC_2022_11_30.pdf2022-11-30T15:48:21.000Z"17c1965294ae88bf93d6f42141f40836"862489STANDARDattachment/Enzalutamide_01_16_19_FDA.pdf2019-03-04T21:26:19.000Z"7f73994116152a34cae86a7bbf16738d"2036032STANDARDattachment/Enzalutamide_Jan_19_17.pdf2017-02-24T21:35:47.000Z"1264ec94367b56b0f36f920b528132fa"842903STANDARDattachment/Epinephrine_4_8_2022.pdf2022-04-08T19:02:24.000Z"cded965abff6ba3750578547100ba649"182301STANDARDattachment/Eplontersen_2024_07_05_HCSC.pdf2024-07-06T00:27:26.000Z"dc5eda945a0d1e3986205b1517251410"1034556STANDARDattachment/Eplontersen_2025_06_04_EMA.pdf2025-06-04T17:53:41.000Z"762ac5a6785c1955f4b8dcc58ebea4af"CRC64NVMEFULL_OBJECT842249STANDARDattachment/Eplontersen_FDA_2024_03_05.pdf2024-03-05T17:10:51.000Z"8e84fd1211714b4a8512d32f8b9509f2"2195502STANDARDattachment/Erbitux_EMA_EPAR_12_17_2012.pdf2016-11-16T19:45:04.000Z"5e2af5575f1bc7829d9ecd26d2109f4e"331563STANDARDattachment/Erdafitinib_05_14_2019_FDA.pdf2019-05-14T19:51:41.000Z"cdabaac16f433c53032472689022d7e4"473853STANDARDattachment/Erdafitinib_2024_08_06_HCSC.pdf2024-08-06T22:01:40.000Z"d70570db897677a3cd4aecb356aa2bee"668046STANDARDattachment/Erdafitinib_2024_10_03_EMA.pdf2024-10-03T23:28:31.000Z"2d3c782f44dd2b1c0d6a4293072ebcad"902357STANDARDattachment/Erdafitinib_2024_10_03_FDA.pdf2024-10-03T23:52:01.000Z"62598f9bb0969b0399db074fd2d1a50c"1761932STANDARDattachment/Erdafitinib_2024_10_03_HCSC.pdf2024-10-04T00:07:51.000Z"855f08a586e17da1fec4f294854fa33c"892346STANDARDattachment/Erdafitinib_HCSC_2022_11_30.pdf2022-11-30T16:27:02.000Z"03046701a991a09dd0ec864bf25b1a72"1318038STANDARDattachment/Eribulin_05_14_2019_FDA.pdf2019-05-15T03:31:54.000Z"4abd919236a3a5a5346440f94417bee2"884091STANDARDattachment/Erlotinib_06_21_19_EMA.pdf2019-06-21T17:35:50.000Z"a1ba30bc617a18da0fddb8400bd01bf7"988847STANDARDattachment/Erlotinib_07_20_2017_FDA.pdf2019-03-04T21:27:10.000Z"a77e42bba692c277c6fc2c440de6ae18"1389644STANDARDattachment/Erlotinib_HCSC_06_01_15.pdf2016-11-16T19:47:32.000Z"76a3705580a62fcd7f5082f3ed93e385"1426570STANDARDattachment/Erlotinib_PMDA_10_05_16.pdf2016-11-16T19:46:36.000Z"534e8b3e33e04af5b058dbee959984c2"578824STANDARDattachment/Erlotinib_label_11_06.pdf2016-11-16T19:44:35.000Z"1f0815cfc96d4d79a210be3b07c3c6f4"375258STANDARDattachment/Erlotinib_label_2013_10.pdf2016-11-16T19:45:22.000Z"6d00ad4ca484443ee25b7e248292ab05"507044STANDARD